3,5-Disubstituted pyrazole compounds as kinase inhibitors and their applications

JP2022547294A5Active Publication Date: 2024-11-13IMPACT THERAPEUTICS (SHANGHAI) INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022514802
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-03-06
Filing Date
2020-09-03
Publication Date
2024-11-13
Estimated Expiration
2040-09-03

AI Technical Summary

Technical Problem

There is a need for new compounds that can effectively inhibit CHK1 kinase, particularly in cancer therapy, as existing inhibitors may not adequately address chemotherapy and radiotherapy resistance in cancer cells.

Method used

Development of novel 3,5-disubstituted pyrazole compounds and their pharmaceutically acceptable forms, including salts, geometric isomers, enantiomers, and prodrugs, which act as potent CHK1 kinase inhibitors.

Benefits of technology

These compounds target CHK1 kinase, potentially enhancing cancer treatment by inhibiting cell cycle checkpoints, leading to cancer cell death and reducing chemotherapy resistance.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides novel compounds of Formula I, where A0-A2, R0-R6, L, Z, and Q are defined herein. The compounds of Formula I are CHK1 inhibitors. Thus, the compounds of the present invention are applicable to the treatment of diseases, disorders, and conditions associated with continued activation of CHK1 or elevated internal DNA damage or lesions during DNA replication, such as cancer. TIFF2022547294000057.tif50141
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to the field of medicinal chemistry. Specifically, it relates to 3,5-disubstituted pyrazole compounds and their applications as therapeutically effective kinase inhibitors and anticancer agents. [Background technology]

[0002] Eukaryotic cells grow and proliferate through a process called mitosis, in which a mother cell divides into two daughter cells that possess identical genetic information. This process of cell proliferation and division is called the cell cycle. The cell cycle consists of four phases: the G1 phase, in which a large amount of proteins, RNA, etc., are synthesized to prepare the cell for DNA synthesis; the S phase, in which DNA is replicated; the G2 phase, a preparatory phase before mitosis in which the cell verifies the accuracy of DNA replication; and the M phase, in which mitosis occurs. During replication, to ensure the accuracy and integrity of genetic material, cells are equipped with complex and precise signaling pathways such as DNA repair, cell cycle checkpoints, and apoptosis to monitor DNA damage and respond accordingly. This network of signaling pathways is called the DNA Damage Response (DDR) pathway.

[0003] When DNA damage occurs, in addition to DNA repair mechanisms, cell cycle checkpoints are also activated. These include the G1 / S checkpoint, Intra-S or S checkpoint, and G2 / M checkpoint, which prevent the cell from entering mitosis (Lobrich M et al. Nature reviews Cancer 2007, 7(11):861-869). In the response process to DNA damage, the DDR pathway is activated, and the detection and repair of damaged DNA are carried out by a series of complex mechanisms. Cell cycle checkpoint kinases CHK1 and CHK2 play a crucial role in the DDR pathway.

[0004] The serine / threonine kinase CHK1 protein (Sanchez Y et al., Science, 1997, 277(5331):1497-1501) is a central component of cell cycle regulation, particularly the G2 / M checkpoint ATR-CHK1-CDC25C axis. Upon recognition of DNA damage signals, ATR is activated, which phosphorylates CHK1 at multiple serine sites, thereby activating CHK1. Activated CHK1 further phosphorylates downstream CDC25, leading to its degradation. This degradation reduces the activation of CDK1 and CDK2 by CDC25, and the inactivation of CDK1 and CDK2 inhibits cell cycle processes, resulting in cell survival after DNA damage repair (Carrassa L et al., Cell Cycle 2011, 10(13):2121-2128). Therefore, targeting CHK1 and inhibiting its activity disrupts cell cycle checkpoints and DNA repair, leading to the accumulation of unrepaired, damaged DNA and ultimately cell death.

[0005] CHK1 protein kinase is highly expressed in various cancer cells, including breast, colon, liver, and gastric cancers. Insensitivity or resistance of some cancer cells to chemotherapy, radiotherapy, and other anticancer drugs is often associated with CHK1 hyperactivation (Bao S et al. Nature 2006, 444(7120):756-760). One of the hottest areas in anticancer research today is promoting apoptosis in cancer cells by regulating cell cycle checkpoints, such as inhibiting CHK1 kinase. This provides a scientific basis for developing CHK1 inhibitors as anticancer agents.

[0006] Several CHK1 kinase inhibitors with various structures are already known. For example, aryl / heteroarylurea compounds are disclosed as CHK1 kinase inhibitors in WO03 / 10444 and WO2005 / 072333; substituted urea compounds are disclosed as CHK1 kinase inhibitors in WO02 / 070494, WO2006 / 021002, WO2006 / 105262 and WO2006 / 014359; and substituted pyrazole compounds are disclosed as CHK1 kinase inhibitors in WO2005 / 009435, WO2010 / 077758, WO2012 / 064548, WO2015 / 120390 and WO2017 / 132928.

[0007] However, there is still a need for novel compounds that can be used as potential inhibitors of CHK1 and are beneficial for cancer treatment. [Overview of the project]

[0008] The present invention provides novel 3,5-disubstituted pyrazole compounds of formulas I, IIa, IIb, III, and IV, or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates, or prodrugs as kinase inhibitors, particularly CHK1 kinase inhibitors.

[0009] Furthermore, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula I, IIa, IIb, III, or IV or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug applicable to cancer treatment.

[0010] In one specific embodiment, the pharmaceutical composition may further include one or more pharmaceutically acceptable carriers or diluents for the treatment of cancer.

[0011] In one specific embodiment, the pharmaceutical composition may further contain at least one known anticancer agent or a pharmaceutically acceptable salt thereof for the treatment of cancer.

[0012] Furthermore, the present invention relates to a method for producing novel compounds of formulas I, IIa, IIb, III, and IV or their pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates, or prodrugs. [Modes for carrying out the invention]

[0013] It should be understood that the features of the embodiments described herein can be arbitrarily combined to form the technical solution of the present invention. Here, the definitions of each group apply to any of the embodiments described herein. For example, here the definition of alkyl substituents applies to any of the embodiments described herein unless alkyl substituents are explicitly defined in the embodiments.

[0014] The term "hydrogen (H)" used here includes its isotopes D and T.

[0015] The term "alkyl group" as used herein refers to the alkyl group itself or a linear or branched radical of up to 10 carbon atoms. The alkyl groups that can be used are linear or branched C1-C. 10 The alkyl group includes an alkyl group, preferably a C1-C6 alkyl group. In some embodiments, the alkyl group is a C1-C4 alkyl group. Typical C1-C 10 Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, hexyl, and octyl groups.

[0016] The term "alkylene group" as used herein refers to an alkyl group, as defined above, that is located between two other chemical groups and used to connect them. Typical alkylene groups include, but are not limited to, methylene, ethylidene, propylene, and butylene groups.

[0017] The term "alkoxy group" used here, for example, the methoxy group and the ethoxy group, refers to the above C1-C10 This refers to oxygen substituted with an alkyl group, preferably a C1-C6 alkyl group or a C1-C4 alkyl group. The alkyl group within the alkoxy group may be substituted. Substituents for the alkoxy group include, but are not limited to, halogens, morpholinyl groups (including morpholino groups), amino groups (including alkylamino and dialkylamino groups), and carboxyl groups (including their esters).

[0018] The "amino group" used here can be represented as -NR′R′′. R′ and R′′ are each independently hydrogen atoms, or may be substituted C1-C. 10 The amino group may be an alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group; or R′ and R′′, together with the N to which they are attached, form an optionally substituted 4-7 membered cyclic amino group, the cyclic amino group may contain one or more (e.g., two or three) other heteroatoms selected from O, N, and S. The amino group may preferably contain NH2, and an amino group in which at least one of R′ and R′′ is a C1-C6 alkyl group.

[0019] The term “aryl group,” used here alone or as part of another substituent, refers to a monocyclic, bicyclic, or tricyclic aromatic group containing 6–14 carbon atoms. The aryl group may be substituted with one or more substituents described herein.

[0020] The aryl groups that can be used are C6-C 14 Aryl group, preferably C6-C 10 It contains an aryl group. Typical C6-C 14 Aryl groups include phenyl, naphthalene, phenanthryl, anthrasyl, indenyl, azuryl, biphenyl, biphenylene, and fluorenyl groups.

[0021] The cycloalkyl groups that can be used are C3-C8 cycloalkyl groups. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl groups. The C3-C8 cycloalkyl groups may be substituted with one or more substituents listed herein.

[0022] Usable halogens or halogen groups include fluoro, chloro, bromo, and iodine.

[0023] The usable acylamino groups are any C1-C6 acyl (alkanoyl) groups linked to an amino nitrogen, such as acetamide, propionamide, butanoiramide, pentanoiramide, and hexanoiramide, as well as aryl-substituted C1-C6 acylamino groups, such as benzoiramide. The usable acyl groups include C1-C6 acyl groups, such as the acetyl group. The acyl group may be substituted with substituents selected from aryl groups and halogens, and the aryl group may be substituted. If the acyl group is substituted with a halogen, the number of halogen substituents may be in the range of 1-5. Examples of substituted acyl groups include the chloroacetyl group and the pentafluorobenzoyl group.

[0024] The term "heterocyclic group" as used herein refers to saturated or partially saturated 3-7 member monocyclic groups, 7-10 member bicyclic groups, spiro groups, or bridging ring groups consisting of a carbon atom and 1-4 heteroatoms independently selected from O, N, and S. In the case of nitrogen and / or sulfur, the heteroatoms may be oxidized, and the nitrogen may be quaternized. The term "heterocyclic group" also includes fused heterocyclic bicyclic systems in which any of the heterocyclic groups defined above are fused to a benzene ring. Heterocyclic groups may be substituted with carbon or nitrogen atoms if a stable compound is obtained. Heterocyclic groups may be substituted with one or more substituents described herein.

[0025] The saturated or partially saturated heterocyclic groups that can be used include tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, 1,4-diazepanyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetrahydroisoquinolinyl, azetidinyl, tetronoyl, and tetramoyl groups. Each may be substituted with one or more substituents listed herein.

[0026] The term "heteroaryl group (heteroaromatic ring)" as used herein refers to a substituent having 5–14 ring atoms containing 6, 10, or 14 π electrons shared in the ring system. The ring atoms of a heteroaryl group are a carbon atom and 1–3 heteroatoms selected from oxygen, nitrogen, and sulfur. A heteroaryl group may be substituted with one or more substituents as described herein.

[0027] The heteroaryl groups that can be used include thienyl (thiophenyl) group, benzo[d]isothiazole-3-yl group, benzo[b]thienyl group, naphtho[2,3-b]thienyl group, thianthrenyl group, furyl (furanyl) group, pyranyl group, isobenzofuranyl group, clomenyl group, xanthenyl group, phenoxanthinyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, and pyridyl (pyridinyl group: 2-pyridyl group, 3-pyridyl group) Groups including but not limited to the 4-pyridyl group, pyrazinyl group, pyrimidinyl group, pyridadinyl group, indolidinyl group, isoindolyl group, 3H-indolyl group, indolyl group, indazolyl group, prinyl group, 4H-quinolidinyl group, isoquinolyl group, quinolyl group, phthalazinyl group, naphthylidinyl group, quinozalinyl group, cinolinyl group, pteridinyl group, carbazolyl group, β-carbolinyl group, phenant Lysinyl group, acridinyl group, perimidinyl group, phenanthrolinyl group, phenazinyl group, isothiazolyl group, phenothiazinyl group, isoxazolyl group, flazanyl group, phenoxazinyl group, 1,4-dihydroquinoxaline-2,3-dione group, 7-aminoisocoumarin group, pyridopyrimidine-4-one group, tetrahydropyridopyrimidinyl group, tetrahydrocyclopenta[c]pyrazole-3-yl group, benzoiso The group includes sazolyl groups, such as 1,2-benzoisoxazole-3-yl group, benzimidazolyl group, 2-oxyndryl group, thiadiazolyl group, 2-oxobendisoxazole group, imidazopyridazinyl group, imidazopyridyl group, triazolopyridazinyl group, tetrahydropyridopyrimidinyl group, pyrazolopyrimidinyl group, pyrrolopyrimidinyl group, pyrrolopyridyl group, pyrrolopyrazinyl group, or triazolopyramidinyl group. If the heteroaryl group contains a nitrogen atom in the ring, that nitrogen atom may be an N-oxide, such as pyridyl-N-oxide, pyrazinyl-N-oxide, and pyrimidinyl-N-oxide.

[0028] In the present invention, unless otherwise specified, the alkyl group, cycloalkyl group, alkylene group, alkoxy group, acylamino group, carbonyl group, heterocyclic group, aryl group or heteroaryl group described in the embodiments herein may be substituted by one or more (e.g., 1, 2, 3, or 4) substituents selected from the following group: halogen, cyano group, nitro group, hydroxy group, carboxyl group, C1-C6 acylamino group, C1-C6 alkoxy group, aryloxy group, C1-C6 alkyl group, C1-C6 acyl group, C6-C 10 aryl group, C3-C8 cycloalkyl group, heterocyclic group or heteroaryl group and carbonyl group, etc. Also, one or more substituents themselves may be substituted. The substituents preferably include, but are not limited to, halogen, carbonyl group, C1-C6 acylamino group, C1-C6 alkoxy group, C1-C6 alkyl group and C1-C6 acyl group.

[0029] In any embodiment of the present invention, when the substituent is a heterocyclic group, aryl group or heteroaryl group, it should be understood that the number is usually 1. Also, the connection or substitution between the substituents in the present invention needs to follow the valence bond theory; unless otherwise specified, when not following the valence bond theory, it should be understood that H is usually used for supplementation.

[0030] In particular, the present invention provides a compound represented by Formula I or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate or prodrug thereof:

Chemical formula

[0031] A0, A1 and A2 are independently selected from N or CR a ; R0 is selected from the group consisting of hydrogen, cyano group, alkyl group, alkoxy group and carbonyl group, and the alkyl group, alkoxy group and carbonyl group may be substituted; R1 is selected from the group consisting of halogens, hydroxyl groups, and optionally substituted alkoxy groups; R2-R4 are independently selected from the group consisting of hydrogen, hydroxyl group, halogen, alkyl group, alkoxy group, nitro group, carbonyl group, and acylamino group, and the alkyl group, alkoxy group, carbonyl group, and acylamino group may be substituted; R5 is selected from the group consisting of hydrogen, an optionally substituted alkyl group, and an optionally substituted alkoxy group; R6 is selected from the group consisting of hydrogen, halogens, and optionally substituted alkyl groups; L is a bond, -C(R b )2-, O, S or NR b is; Z is a bond or an alkylene group; Q is a heterocyclic group that can be substituted; R a is selected from the group consisting of H, optionally substituted alkyl groups, and halogens; R b These are independently selected from the group consisting of hydrogen and optionally substituted alkyl groups.

[0032] In the compound of formula I, each alkyl group is independently a C1-C6 alkyl group, preferably a C1-C4 alkyl group; each alkylene group is independently a C1-C6 alkylene group, preferably a C1-C4 alkylene group; preferably, if an alkyl group (including alkyl groups within an alkoxy group) is substituted, one or more substituents may be selected from the group consisting of amino groups, cyano groups, hydroxyl groups, nitro groups, halogen groups, and carboxyl groups, and the number of substituents may be 1 to 5. For example, the substituted alkyl group may be a hydroxyalkyl group, a dihydroxyalkyl group, or a halogenated alkyl group; the substituted alkoxy group may be a halogenated alkoxy group, and so on. When one or more substituents are cyano groups, nitro groups, and carboxyl groups, the number of substituents is usually 1; when one or more substituents are halogens, for example, the number of substituents may reach up to 5 halogen groups, depending on the carbon chain length of the alkyl group; it should be understood that examples of such one or more substituents include trifluoromethyl groups, pentafluoroethyl groups, and the like.

[0033] In the compound of formula I, preferably, R a is H or C 1-3 It is an alkyl group; more preferably, A0 and A1 are N or CH; A2 is N, CH or CCH3. More preferably, A0 and A1 are N; A2 is CH.

[0034] In the compound of formula I, preferably R0 is a cyano group, C 1-3 Alkyl alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 It is an alkyl group.

[0035] In the compound of formula I, preferably R1 is a halogen, a hydroxyl group, and C 1-3 Alkoxy group or halogenated C 1-3 It is an alkoxy group.

[0036] In the compound of formula I, preferably, when R2-R4 are substituted, one or more substituents may be selected from the group consisting of hydroxyl groups, halogens, and amino groups. R2-R4 are preferably independently hydrogen, halogen, C1-C3 alkyl group, C1-C3 alkoxy group, or halogenated C 1-3 It is an alkyl group. More preferably, R2-R4 are independently hydrogen, halogen, C1-C3 alkyl group and halogenated C 1-3 Selected from the group consisting of alkyl groups. In some embodiments, R2-R4 are each hydrogen. In some embodiments, only one of R2-R4 is a halogen, a C1-C3 alkyl group, or a halogenated C 1-3 It is an alkyl group, and preferably the other group of R2-R4 is H.

[0037] In the compound of formula I, R5 is preferably hydrogen or a C1-C3 alkyl group.

[0038] In the compound of formula I, R6 is preferably hydrogen or a C1-C3 alkyl group.

[0039] In the compound of formula I, preferably L is C 1-3 Alkylene group, O, S, or NR b And R b Preferably hydrogen or C 1-3 It is an alkyl group.

[0040] In the compound of formula I, preferably Z is C 1-3 An alkylene group, more preferably a methylene group.

[0041] In the compound of formula I, preferably one or more substituents on Q are selected from the group consisting of halogens, hydroxyl groups, amino groups, carboxyl groups, optionally substituted alkyl groups, optionally substituted alkoxy groups, optionally substituted aryl groups, optionally substituted heteroaryl groups, and optionally substituted heterocyclic groups. One or more substituents on optionally substituted alkyl groups and alkoxy groups may also be one or more substituents selected from the group consisting of amino groups, halogens, hydroxyl groups, and carboxyl groups. For example, the alkyl group may be substituted with -NR′R′′, where R′ and R′′ are defined herein and are preferably independently H or C1-C6 alkyl groups; one or more substituents on optionally substituted aryl groups, heteroaryl groups, and heterocyclic groups may also be one or more substituents selected from the group consisting of amino groups, halogens, hydroxyl groups, carboxyl groups, alkyl groups, and alkoxy groups. Preferably, one or more substituents on Q are located at ortho, meta, and / or para positions relative to the connection position, rather than at the connection position.

[0042] More preferably, in the compound of formula I, the heteroatom of Q may be selected from N, O, and S. Preferably, Q contains 1 to 3 heteroatoms. More preferably, Q is an unsubstituted saturated 3-7 membered heterocyclic group or C which may be 1-2 substituted. 1-3 A saturated 3-7 membered heterocyclic group substituted with an alkyl group, where one or more substituents are located at ortho, meta, and / or para positions relative to the connection position, rather than at the connection position. The heterocyclic group preferably includes, but is not limited to, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), tetrahydropyranyl, and azetidinyl groups. Q preferably includes the following group:

[0043] [ka]

[0044] * indicates the position where the substituent connects to the rest of the compound.

[0045] The compound represented by formula I of the present invention may also have the structure represented by the following formula IIa:

[0046] [ka]

[0047] A0 is N or CR a To be selected from; R0 is selected from the group consisting of hydrogen, cyano group, alkyl group, alkoxy group, and carbonyl group, and the alkyl group, alkoxy group, and carbonyl group may be substituted; R1 is selected from the group consisting of halogens, hydroxyl groups, and optionally substituted alkoxy groups; R2-R4 are independently selected from the group consisting of hydrogen, halogen, alkyl group, alkoxy group, nitro group, carbonyl group, and acylamino group, and the alkyl group, alkoxy group, carbonyl group, and acylamino group may be substituted; R5 is selected from the group consisting of hydrogen, an optionally substituted alkyl group, and an optionally substituted alkoxy group; L is a bond, -C(R b )2-, O, S or NR b is; Z is a bond or an alkylene group; Q is a substituted heterocyclic group, where one or more substituents are located at ortho, meta, and / or para positions relative to the connection site, rather than at the connection site; R a is selected from the group consisting of H, optionally substituted alkyl groups, and halogens; R b is independently hydrogen or an optionally substituted alkyl group; In the compound of formula IIa, each alkyl group is independently a C1-C6 alkyl group, preferably a C1-C4 alkyl group; each alkylene group is independently a C1-C6 alkylene group, preferably a C1-C4 alkylene group. Preferably, when an alkyl group (including alkyl groups within an alkoxy group) is substituted, one or more substituents may be selected from the group consisting of amino, cyano, hydroxyl, nitro, halogen, and carboxyl groups, and the number of substituents may be 1 to 5. For example, the substituted alkyl group may be a hydroxyalkyl group, a dihydroxyalkyl group, or a halogenated alkyl group; the substituted alkoxy group may be a halogenated alkoxy group, and so on. When the substituents are cyano, nitro, and carboxyl groups, the number of substituents is usually 1; when one or more substituents are halogens, for example, the number of substituents may reach up to 5 halogen groups depending on the carbon chain length of the alkyl group; it should be understood that examples of such substituents include trifluoromethyl and pentafluoroethyl groups.

[0048] In the compound of formula IIa, A0 is preferably N or CH.

[0049] In the compound of formula IIa, preferably R0 is a cyano group, C 1-3 Alkyl alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 It is an alkyl group.

[0050] In the compound of formula IIa, preferably R1 is a halogen, a hydroxyl group, a C1-C3 alkoxy group, or a halogenated C 1-3 It is an alkoxy group, more preferably C 1-3 Alkoxy group or halogenated C 1-3 It is an alkoxy group.

[0051] In the compound of formula IIa, preferably, when R2-R4 are substituted, one or more substituents may be selected from the group consisting of hydroxyl groups, halogens, and amino groups. R2-R4 are preferably independently hydrogen, halogen, C1-C3 alkyl group, C1-C3 alkoxy group, and halogenated C 1-3 Selected from the group consisting of alkyl groups. More preferably, R2-R4 are independently hydrogen, halogen, and C 1-3 Alkyl and halogenated C 1-3 Selected from the group consisting of alkyl groups. In some embodiments, R2-R4 are each hydrogen. In some embodiments, only one of R2-R4 is a halogen, a C1-C3 alkyl group, or a halogenated C 1-3 It is an alkyl group, and preferably the other group is H.

[0052] In the compound of formula IIa, R5 is preferably hydrogen or a C1-C3 alkyl group.

[0053] In the compound of formula IIa, preferably L is C 1-3 Alkylene group, O, S, or NR b And R b Preferably hydrogen or C 1-3 It is an alkyl group.

[0054] In the compound of formula IIa, preferably Z is C 1-3 An alkylene group, more preferably a methylene group.

[0055] In the compounds of formula IIa, Q is preferably a piperidinyl group, a piperazinyl group, a pyrrolidinyl group, a morpholinyl group (e.g., a morpholino group), a thiomorpholinyl group (e.g., a thiomorpholino group), a tetrahydropyranyl group, and an azetidinyl group. Each of these may be substituted. Preferably, one or more substituents on Q are selected from the group consisting of halogens, hydroxyl groups, amino groups, carboxyl groups, optionally substituted alkyl groups, optionally substituted alkoxy groups, optionally substituted aryl groups, optionally substituted heteroaryl groups, and optionally substituted heterocyclic groups. One or more substituents on optionally substituted alkyl groups and alkoxy groups may be one or more substituents selected from the group consisting of amino groups, halogens, hydroxyl groups, and carboxyl groups. For example, alkyl groups may be substituted with -NR′R′′. R′ and R′′ are defined above and are preferably independently H or C1-C6 alkyl groups; one or more substituents on the substituted aryl, heteroaryl, and heterocyclic groups may be one or more substituents selected from the group consisting of amino groups, halogens, hydroxyl groups, carboxyl groups, alkyl groups, and alkoxy groups. Preferably, one or more substituents on Q are in ortho, meta, and / or para positions with respect to the connection site.

[0056] More preferably, in the compound of formula IIa, the heteroatom of Q may be selected from N, O, and S. Preferably, Q contains 1 to 3 heteroatoms. More preferably, Q is an unsubstituted saturated 3-7 membered heterocyclic group or C which may be 1-2 substituted. 1-3 A saturated 3-7 membered heterocyclic group substituted with an alkyl group, where one or more substituents are located at ortho, meta, and / or para positions relative to the connection position, rather than at the connection position. The heterocyclic group preferably includes, but is not limited to, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), tetrahydropyranyl, and azetidinyl groups. Q preferably includes the following group:

[0057] [ka]

[0058] * indicates the position where the substituent connects to the rest of the compound.

[0059] A preferred set of compounds in the present invention is a compound represented by formula IIb or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug:

[0060] [ka]

[0061] R0-R4 and L are described in any of the embodiments of Formula I described above; Q may be an unsubstituted saturated 3-7 membered heterocyclic group or a 1-2 substituted C. 1-3 A saturated 3-7 membered heterocyclic group substituted with an alkyl group, wherein one or more substituents are located at ortho, meta, and / or para positions relative to the connection position, rather than at the connection position.

[0062] In the compound of formula IIb, preferably R0 is a cyano group, C 1-3 Alkyl alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 It is an alkyl group.

[0063] In the compound of formula IIb, R1 is preferably a halogen, a hydroxyl group, a C1-C3 alkoxy group, or a halogenated C1-C3 alkoxy group.

[0064] In the compound of formula IIb, preferably R2-R4 are independently hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy group or halogenated C1-C3 alkyl; more preferably R2-R4 are independently hydrogen, halogen, C1-C3 alkyl or halogenated C1-C3 alkyl; in some embodiments, R2-R4 are each hydrogen; in some embodiments, only one of R2-R4 is halogen, C1-C3 alkyl or halogenated C 1-3 It is an alkyl group.

[0065] In the compound of formula IIb, preferably L is C 1-3 Alkylene group, O, S, or NR b And R b Preferably hydrogen or C 1-3 It is an alkyl group.

[0066] In compounds of formula IIb, the heterocyclic group Q preferably includes, but is not limited to, a piperidinyl group, a piperazinyl group, a pyrrolidinyl group, a morpholinyl group (e.g., a morpholino group), a thiomorpholinyl group (e.g., a thiomorpholino group), a tetrahydropyranyl group, and an azetidinyl group. Q preferably includes the following group:

[0067] [ka]

[0068] More preferably, Q is one of the following groups:

[0069] [ka]

[0070] * indicates the position where the substituent connects to the rest of the compound.

[0071] A preferred set of compounds in the present invention is a compound represented by formula III or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug:

[0072] [ka]

[0073] R1, R3, and Q are described in any of the embodiments of formulas I, IIa, and IIb above.

[0074] In the compound of formula III, R1 is preferably a halogen, a hydroxyl group, a C1-C3 alkoxy group, or a halogenated C1-C3 alkoxy group.

[0075] In the compound of formula III, preferably R3 is hydrogen, halogen, C1-C3 alkyl group, C1-C3 alkoxy group or halogenated C1-C3 alkyl group; more preferably R3 is hydrogen, halogen, C1-C3 alkyl group or halogenated C1-C3 alkyl group.

[0076] In the compound of formula III, Q is an unsubstituted saturated 3-7 membered heterocyclic group or a C that may be 1-2 substituted. 1-3 Q is a saturated 3-7 membered heterocyclic group substituted with an alkyl group, where one or more substituents are located at ortho, meta, and / or para positions relative to the connection position, rather than at the connection position. The heterocyclic group of Q preferably includes, but is not limited to, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), tetrahydropyranyl, and azetidinyl groups. Q preferably includes the following groups:

[0077] [ka]

[0078] More preferably, Q is one of the following groups:

[0079] [ka]

[0080] * indicates the position where the substituent connects to the rest of the compound.

[0081] A preferred set of compounds in the present invention is a compound represented by formula V or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug:

[0082] [ka]

[0083] A0, A1, A2, R0-R6, L, and Z are defined in any of the embodiments described above; A3 is either CH or N; Ring Q is a 3-7 member heterocyclic group; R7 is selected from the group consisting of halogens, hydroxyl groups, amino groups, carboxyl groups, optionally substituted alkyl groups, optionally substituted alkoxy groups, optionally substituted aryl groups, optionally substituted heteroaryl groups, and optionally substituted heterocyclic groups; n is an integer selected from the group consisting of 0-3, preferably 0-2.

[0084] In the compound of formula IV, ring Q is preferably a 3-7 membered heterocyclic group containing one or two heteroatoms selected from the group consisting of O, S, and N. Preferably, ring Q is selected from the group consisting of piperidinyl group, piperazinyl group, pyrrolidinyl group, morpholinyl group (e.g., morpholino group), thiomorpholinyl group (e.g., thiomorpholino group), tetrahydropyranyl group, and azetidinyl group.

[0085] In the compound of formula IV, R7 is preferably a C1-C3 alkyl group. In some embodiments, n is 0.

[0086] In the compound of formula IV, each alkyl group is independently a C1-C6 alkyl group, preferably a C1-C4 alkyl group; each alkylene group is independently a C1-C6 alkylene group, preferably a C1-C4 alkylene group; preferably, if an alkyl group (including alkyl groups in alkoxy groups) is substituted, one or more substituents may be selected from the group consisting of amino groups, cyano groups, hydroxyl groups, nitro groups, halogen groups, and carboxyl groups, and the number of substituents may be 1 to 5. For example, the substituted alkyl group may be a hydroxyalkyl group, a dihydroxyalkyl group, or a halogenated alkyl group; the substituted alkoxy group may be a halogenated alkoxy group, and so on. When one or more substituents are cyano groups, nitro groups, and carboxyl groups, the number of substituents is usually 1; when one or more substituents are halogens, for example, the number of substituents may reach up to 5 halogen groups depending on the carbon chain length of the alkyl group; it should be understood that examples of such one or more substituents include trifluoromethyl groups, pentafluoroethyl groups, and the like.

[0087] In the compound of formula IV, preferably, R a is H or C 1-3 It is an alkyl group; more preferably, A0 and A1 are N or CH; A2 is N, CH or CCH3. More preferably, A0 and A1 are N; A2 is CH.

[0088] In the compound of formula IV, preferably R0 is a cyano group, C 1-3 Alkyl alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 It is an alkyl group.

[0089] In the compound of formula IV, preferably R1 is a halogen, a hydroxyl group, and C 1-3Alkoxy group or halogenated C 1-3 It is an alkoxy group.

[0090] In the compound of formula IV, preferably, when R2-R4 are substituted, one or more substituents may be selected from the group consisting of hydroxyl groups, halogens, and amino groups. R2-R4 are preferably independently hydrogen, halogen, C1-C3 alkyl group, C1-C3 alkoxy group, or halogenated C 1-3 It is an alkyl group. More preferably, R2-R4 are independently hydrogen, halogen, C1-C3 alkyl group and halogenated C 1-3 Selected from the group consisting of alkyl groups. In some embodiments, R2-R4 are each hydrogen. In some embodiments, only one of R2-R4 is a halogen, a C1-C3 alkyl group, or a halogenated C 1-3 It is an alkyl group, and preferably the other group of R2-R4 is H.

[0091] In the compound of formula IV, R5 is preferably hydrogen or a C1-C3 alkyl group; more preferably, R5 is hydrogen.

[0092] In the compound of formula IV, R6 is preferably hydrogen, a halogen, or a C1-C3 alkyl group; more preferably, R6 is hydrogen.

[0093] In the compound of formula IV, preferably L is C 1-3 Alkylene group, O, S, or NR b And R b Preferably hydrogen or C 1-3 It is an alkyl group.

[0094] In the compound of formula IV, preferably Z is C 1-3 An alkylene group, more preferably a methylene group.

[0095] In the compound of formula IV, preferably -(R7) n The ring Q which may be substituted by the following group is selected from the following group:

[0096] [ka]

[0097] * indicates the position where the substituent connects to the rest of the compound.

[0098] In the compound of formula IV, preferably, A0 is N; A1 is N; A2 is CH; A3 is CH; R0 is a cyano group; R1 is a halogen, a hydroxyl group, or a C1-C3 alkoxy group; R2 is hydrogen; R3 is hydrogen, a halogen, a C1-C3 alkyl group, or a halogenated C 1-3 It is an alkyl group; R4 is hydrogen; R5 is hydrogen; R6 is hydrogen; L is O; Z is C 1-3 The ring Q is an alkylene group, more preferably a methylene group; the ring Q is an unsubstituted saturated 3-7 membered heterocyclic group; preferably, the unsubstituted saturated 3-7 membered heterocyclic group is selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), and azetidinyl groups; and n is 0.

[0099] In some embodiments of formula IV, preferably, A0 is N; A1 is N; A2 is CH; A3 is CH; R0 is a cyano group; R1 is a C1-C3 alkoxy group; R2 is hydrogen; R3 is hydrogen, halogen, or C1-C3 alkyl group; R4 is hydrogen; R5 is hydrogen; R6 is hydrogen; L is O; Z is C 1-3 The ring Q is an alkylene group, more preferably a methylene group; the ring Q is an unsubstituted saturated 3-7 membered heterocyclic group; preferably the unsubstituted saturated 3-7 membered heterocyclic group is selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, and thiomorpholinyl groups; and n is 0.

[0100] Preferred embodiments of the compound of formula I include, but are not limited to, the following: (S)-5-((5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 1); (S)-5-((5-(2-Methoxy-6-(Morpholin-2-ylmethoxy)phenyl)-1H-Pyrazole-3-yl)amino)Picolinonitrile (Example 2); (R)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 3); (S)-5-((5-(2-methoxy-6-((4-methylmorpholine-2-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 4); (S)-N-(5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)-5-(trifluoromethyl)pyrazine-2-amine (Example 5);

[0101] (S)-N-(5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)-5-methylpyrazine-2-amine (Example 6); (R)-5-((5-(2-Methoxy-6-(Morpholin-3-ylmethoxy)phenyl)-1H-Pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 7); (S)-5-((5-(2-methoxy-6-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 8); (S)-5-((5-(2-Methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 9); (S)-5-((5-(2-Methoxy-6-(piperazin-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 10);

[0102] (S)-5-((5-(2-Methoxy-6-((1-methylpiperazine-2-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 11); 5-((5-(2-methoxy-6-(piperidine-4-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 12); (S)-5-((5-(2-methoxy-6-(pyrroridine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 13); (S)-5-((5-(4-fluoro-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 14); (S)-5-((5-(3-chloro-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 15);

[0103] (S)-5-((5-(4-chloro-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 16); (S)-5-((5-(3-chloro-6-methoxy-2-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 17); (S)-5-((5-(4-bromo-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 18); (S)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 19); (S)-5-((5-(2-(Morpholin-2-ylmethoxy)-6-(trifluoromethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 20);

[0104] (S)-5-((5-(2-methoxy-6-((morpholin-2-ylmethyl)amino)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 21); (S)-5-((5-(2-methoxy-6-(methyl(morpholine-2-ylmethyl)amino)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 22); 5-((5-(2-methoxy-6-(2-(piperazin-1-yl)ethyl)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 23); (S)-6-((5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)nicotinonitrile (Example 24); (S)-6-((5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyridazine-3-carbonitrile (Example 25);

[0105] (S)-5-Methoxy-N-(5-(2-Methoxy-6-(Piperidine-3-ylmethoxy)phenyl)-1H-Pyrazole-3-yl)pyrazine-2-amine (Example 26); (S)-5-ethyl-N-(5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)pyrazine-2-amine (Example 27); (S)-5-((5-(2-Methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)-3-methylpyrazine-2-carbonitrile (Example 28); (S)-5-((5-(2-Methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)-6-methylpyrazine-2-carbonitrile (Example 29); 5-((5-(2-methoxy-6-(piperidine-4-yloxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 30);

[0106] 5-((5-(2-(azetidine-3-ylmethoxy)-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 31); (S)-5-((5-(2-Methoxy-6-((1-methylpiperidine-3-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 32); (R)-5-((5-(2-methoxy-6-(piperidine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 33); (S)-5-((5-(2-methoxy-6-((tetrahydro-2H-pyran-3-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 34); (S)-5-((5-(2-ethoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 35);

[0107] (S)-5-((5-(2-isopropoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 36); (S)-5-((5-(3-fluoro-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 37); (S)-5-((5-(4-fluoro-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 38); (S)-5-((5-(4-fluoro-2-methoxy-6-(pyrrolidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 39); (S)-5-((5-(4-chloro-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 40);

[0108] (S)-5-((5-(4-bromo-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 41); (S)-5-((5-(2-methoxy-3-methyl-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 42); (S)-5-((5-(2-methoxy-4-methyl-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 43); (S)-5-((5-(2-methoxy-4-methyl-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 44); (S)-5-((5-(2-Methoxy-6-(piperidine-3-ylmethoxy)-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 45);

[0109] (S)-5-((5-(2-fluoro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 46); (S)-5-((5-(2-chloro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 47); (S)-5-((5-(2-hydroxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 48); (S)-5-((5-(2-((4,4-dimethylpiperidine-3-yl)methoxy)-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 49); 5-((5-(2-((4,4-dimethylpiperidine-3-yl)methoxy)-4-fluoro-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 50);

[0110] (S)-5-((5-(2-Methoxy-6-(piperidine-3-ylmethoxy)phenyl)-4-methyl-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 51); (S)-5-((4-bromo-5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 52); 5-((5-(2-(azetidine-3-ylmethoxy)-6-fluorophenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 53); (S)-5-((5-(2-fluoro-6-(pyrroridine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 54); (S)-5-((5-(2-fluoro-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 55);

[0111] (S)-5-((5-(2,4-difluoro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 56); (S)-5-((5-(4-chloro-2-fluoro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 57); (S)-5-((5-(4-chloro-2-fluoro-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 58); (S)-5-((5-(4-bromo-2-fluoro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 59); (S)-5-((5-(4-bromo-2-fluoro-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 60);

[0112] 5-((5-(2-(azetidine-3-ylmethoxy)-6-fluoro-4-methylphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 61); (S)-5-((5-(2-fluoro-4-methyl-6-(pyrrolidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 62); (S)-5-((5-(2-fluoro-4-methyl-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 63); (S)-5-((5-(2-fluoro-4-methyl-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 64); (R)-5-((5-(2-methoxy-6-(pyrroridine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 65);

[0113] (R)-5-((5-(4-fluoro-2-methoxy-6-(pyrrolidine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 66); 5-((5-(2-(azetidine-3-ylmethoxy)-4-chloro-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 67); (S)-5-((5-(4-chloro-2-methoxy-6-(pyrroridine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 68); 5-((5-(2-(azetidine-3-ylmethoxy)-4-bromo-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 69); (S)-5-((5-(4-bromo-2-methoxy-6-(pyrrolidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 70);

[0114] (R)-5-((5-(4-bromo-2-methoxy-6-(pyrrolidine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 71); 5-((5-(2-(azetidine-3-ylmethoxy)-6-methoxy-4-methylphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 72); (S)-5-((5-(2-methoxy-4-methyl-6-(pyrrolidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 73); (R)-5-((5-(2-methoxy-4-methyl-6-(pyrrolidine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 74); (S)-5-((5-(4-ethyl-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 75);

[0115] (S)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate and (R)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate (Example 76); (S)-5-((5-(4-fluoro-2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate and (R)-5-((5-(4-fluoro-2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate (Example 77); (S)-5-((5-(4-chloro-2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate and (R)-5-((5-(4-chloro-2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate (Example 78); (S)-5-((5-(4-bromo-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate and (R)-5-((5-(4-bromo-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrivilate (Example 79); (S)-5-((5-(2-methoxy-4-methyl-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(2-methoxy-4-methyl-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile (Example 80); or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates or prodrugs thereof.

[0116] Some of the compounds of the present invention may exist as stereoisomers, including optical isomers. The present invention includes all stereoisomers and racemic mixtures thereof, as well as individual enantiomers that can be separated according to methods well known to those skilled in the art.

[0117] In the present invention, examples of pharmaceutically acceptable salts include inorganic and organic salts such as hydrochloride, hydrobromide, phosphate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate, and oxalate; and inorganic and organic base salts formed from bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine), and N-methyl-glucamine.

[0118] Examples of prodrugs of the compounds of the present invention include simple esters of carboxylic acid-containing compounds (e.g., those obtained by condensation with C1-C4 alcohols according to methods known in the art); esters of hydroxyl-containing compounds (e.g., those obtained by condensation with C1-C4 carboxylic acids, C3-C6 diacids or their anhydrides, e.g., succinic anhydride and fumaric anhydride, according to methods known in the art); imines of amino-containing compounds (e.g., those obtained by condensation with C1-C4 aldehydes or ketones according to methods known in the art); carbamates of amino-containing compounds, e.g., those described by Leu et al. (J.Med.Chem. 42:3623-3628 (1999)) and Greenwald et al. (J.Med.Chem. 42:3657-3667 (1999)); and acetals and ketals of alcohol-containing compounds (e.g., those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether, according to methods known in the art).

[0119] The compounds of the present invention can be prepared by methods known to those skilled in the art or by novel methods of the present invention. In particular, the compounds of formula I of the present invention can be prepared as illustrated in Scheme 1. A mixture of 1-(2-hydroxy-6-methoxyphenyl)acetophenone and N,N-dimethylformamide dimethylacetal reacts by heating to obtain (2E)-3-(dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)-2-propenyl-1-one. In ethanol, (2E)-3-(dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)-2-propenyl-1-one reacts by heating with a hydroxyl-l-amine hydrochloride to obtain 3-methoxy-2-(1,2-oxazole-5-yl)phenol. In tetrahydrofuran, triphenylphosphine and diisopropyl azodicarboxylate are stirred at low temperature, and then 3-methoxy-2-(1,2-oxazole-5-yl)phenol and tert-butyl(2S)-2-(hydroxymethyl)morpholine-4-carboxylate are added and reacted at room temperature to obtain tert-butyl(2S)-2-[3-methoxy-2-(1,2-oxazole-5-yl)phenoxymethyl]morpholine-4-carboxylate. In ethanol and water, tert-butyl(2S)-2-[3-methoxy-2-(1,2-oxazole-5-yl)phenoxymethyl]morpholine-4-carboxylate reacts with potassium hydroxide at room temperature to obtain tert-butyl(2S)-2-[2-(2-cyanoacetyl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate. In tetrahydrofuran, water, and methanol, tert-butyl(2S)-2-[2-(2-cyanoacetyl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate and hydrazine hydrate are stirred, acetic acid is added, and the mixture is heated to obtain tert-butyl(2S)-2-[2-(5-amino-2H-pyrazole-3-yl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate.In dimethyl sulfoxide, tert-butyl(2S)-2-[2-(5-amino-2H-pyrazole-3-yl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate, 5-chloropyrazine-2-carbonitride, and N-ethylmorpholine are heated to obtain tert-butyl(2S)-2-(2-[5-[(5-cyanopyrazine-2-yl)amino]-2H-pyrazole-3-yl]-3-methoxyphenoxy)morpholine-4-carboxylate. In dichloromethane, tert-butyl(2S)-2-(2-[5-[(5-cyanopyrazine-2-yl)amino]-2H-pyrazole-3-yl]-3-methoxyphenoxy)morpholine-4-carboxylate reacts with trifluoroacetic acid at room temperature to obtain the target compound (S)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride.

[0120] [ka]

[0121] Other related compounds can be prepared in a similar manner. For example, when 5-chloropyrazine-2-carbonitrile is replaced with 5-bromocyanopyridine, the target compound (S)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)picolinonitrile is obtained; when 5-chloropyrazine-2-carbonitrile is replaced with 2-chloro-5-(trifluoromethyl)pyrazine, the target compound (S)-N-(5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)-5-(trifluoromethyl)pyrazine-2-amine is obtained. When 5-chloropyrazine-2-carbonitrile is replaced with 2-chloro-5-methylpyrazine, the target compound (S)-N-(5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)-5-methylpyrazine-2-amine is obtained. When tert-butyl(2S)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with (S)-(tetrahydro-2H-pyran-2-yl)methanol, the target compound (S)-5-((5-(2-methoxy-6-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When tert-butyl(2S)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl(S)-3-(hydroxymethyl)piperidine-1-carboxylate, the target compound (S)-5-((5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)-1-ethanone is replaced with 1-(4-fluoro-2-hydroxy-6-methoxyphenyl)-1-ethanone, the target compound (S)-5-((5-(4-fluoro-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained.When 1-(2-hydroxy-6-methoxyphenyl)-1-ethanone is replaced with 1-(3-chloro-6-hydroxy-2-methoxyphenyl)-1-ethanone, the target compound (S)-5-((5-(3-chloro-2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)-1-ethanone is replaced with 1-(2-hydroxy-6-(trifluoromethoxy)phenyl)-1-ethanone, the target compound (S)-5-((5-(2-(morpholine-2-ylmethoxy)-6-(trifluoromethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)-1-ethanone is replaced with 1-(2-amino-6-methoxyphenyl)-1-ethanone, the target compound (S)-5-((5-(2-methoxy-6-((morpholine-2-ylmethyl)amino)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)ethanone is replaced with 1-(2-hydroxy-6-ethoxyphenyl)ethanone, the target compound (S)-5-((5-(2-ethoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)ethanone is replaced with 1-(4-chloro-2-hydroxy-6-methoxyphenyl)ethanone, the target compound (S)-5-((5-(4-chloro-2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When 1-(2-hydroxy-6-methoxyphenyl)ethanone is replaced with 1-(4-methyl-2-hydroxy-6-methoxyphenyl)ethanone, the target compound (S)-5-((5-(2-methoxy-4-methyl-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained.When 1-(2-hydroxy-6-methoxyphenyl)ethanone is replaced with 1-(2-fluoro-6-hydroxyphenyl)ethanone, the target compound (S)-5-((5-(2-fluoro-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained.

[0122] The compounds of the present invention can be prepared according to the reactions illustrated in Scheme 2. In DMF, 1-(2-hydroxy-6-methoxyphenyl)ethenone, p-methoxybenzyl chloride (PMBCl), and K2CO3 react at room temperature to obtain 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)ethane-1-one. In anhydrous DMSO, 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)ethane-1-one, t-BuOLi, CS2, and MeI react at room temperature to obtain 1-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-3,3-bis(methylsulfonyl)-2-propen-1-one. In THF, 5-aminopyrazine-2-carbonitride reacts with NaH at low temperature, and then 1-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-3,3-bis(methylsulfonyl)-2-propen-1-one is added and reacted by heating to obtain 5-(((E)-3-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1-methylsulfonyl-3-oxo-1-propenyl)amino)pyrazine-2-carbonitride. In EtOH, 5-(((E)-3-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1-methylsulfonyl-3-oxo-1-propenyl)amino)pyrazine-2-carbonitride, AcOH, and N2H4·H2O react by heating to obtain 5-((5-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride. 5-((5-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride is deprotected under acidic conditions (e.g., HCl in dioxane) at room temperature to obtain 5-((5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-methylnitrile dihydrochloride.In THF, 5-((5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-methylnitrile dihydrochloride, TEA, triphenylline, diisopropyl azodicarboxylate (DIAD), and tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate react upon heating to form tert-butyl(2R)-2-((2-[3-((5-cyanopyrazine-2-yl)amino)-1H-pyrazole-5-yl]-3-methoxy Phenoxy)methyl]morpholine-4-carboxylate is obtained. In DCM, tert-butyl(2R)-2-((2-[3-((5-cyanopyrazine-2-yl)amino)-1H-pyrazole-5-yl]-3-methoxyphenoxy)methyl]morpholine-4-carboxylate and TFA are deprotected at room temperature to obtain the target compound (R)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride.

[0123] [ka]

[0124] Other related compounds can be prepared in a similar manner. For example, when tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl(3S)-3-(hydroxymethyl)morpholine-4-carboxylate, the target compound (R)-5-((5-(2-methoxy-6-(morpholine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with 1-allyloxycarbonyl-4-tert-butoxycarbonyl-(s)-2-hydroxymethylpiperazine, the target compound (S)-5-((5-(2-methoxy-6-(piperazine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained. When tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate, the target compound 5-((5-(2-methoxy-6-(piperidine-4-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride is obtained. When tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl(S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate, the target compound (S)-5-((5-(2-methoxy-6-(pyrrolidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride is obtained. When tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl-4-hydroxy group piperidine-1-carboxylate, the target compound 5-((5-(2-methoxy-6-(piperidine-4-yloxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile is obtained.When tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate is replaced with tert-butyl 2-(hydroxymethyl)thiomorpholine-4-carboxylate, the target compounds (R)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride and (S)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride are obtained.

[0125] One important aspect of the present invention is the discovery that compounds of formula I (including the compounds of formulas IIa, IIb, III, and IV described herein) are kinase inhibitors, particularly CHK1 kinase inhibitors. Accordingly, compounds of formula I (including the compounds of formulas IIa, IIb, III, and IV described herein), their stereoisomers, tautomers, N-oxides, hydrates, solvates, or salts, or mixtures thereof, or prodrugs thereof can be used to treat diseases, disorders, and symptoms associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication, or in the manufacture of pharmaceuticals for treating diseases, disorders, and symptoms associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication.

[0126] In this invention, diseases, disorders, and conditions associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication include cancer. Cancer may be a solid tumor or a hematological malignancy, and includes liver cancer, melanoma, Hodgkin's disease, non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilms' tumor, cervical cancer, testicular cancer, soft tissue sarcoma, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, and small cell lung cancer. This includes, but is not limited to, gastric cancer, colon cancer, malignant islet tumors, malignant carcinoma-like carcinomas, choriocarcinoma, fungal mycoses, head and neck cancers, osteogenic sarcomas, pancreatic cancer, acute myeloid leukemia, pilosetocellular leukemia, rhabdomyosarcoma, Kaposi's sarcoma, urogenital tumors, thyroid cancer, esophageal cancer, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial cancer, polycythemia, idiopathic thrombocytemia, and adrenocortical carcinoma. Preferably, the cancers are associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication; the term “associated” means that it plays a certain role in the development and progression of cancer, for example, leading to the development of cancer and / or promoting the progression or metastasis of cancer.

[0127] Accordingly, the present invention further provides a method for treating or preventing diseases, disorders and symptoms associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication, comprising administering an effective amount of a compound of formula I (including the compounds of formula IIa, IIb, III, and IV described herein) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof to a subject requiring such treatment, or a pharmaceutical composition comprising an effective amount of a compound of formula I (including the compounds of formula IIa, IIb, III, and IV described herein) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof. In the present invention, the subject includes mammals, more specifically humans.

[0128] In carrying out the therapeutic method of the present invention, an effective dose of a pharmaceutical formulation is administered to a patient exhibiting one or more of these symptoms. The pharmaceutical formulation comprises a therapeutically effective concentration of a compound of formula I (including the compounds of formulas IIa, IIb, III, and IV described herein) and is applied to oral, intravenous, topical, or local administration for the treatment of cancer and other diseases. The dose is effective in improving or eliminating one or more symptoms. An effective dose of a compound for treating a particular disease is sufficient to improve or alleviate in some way the symptoms associated with the disease. The dose may be administered as a single dose or according to an effective regimen. The dose may also cure the disease, but is usually administered to improve the symptoms of the disease. Usually, repeated doses are required to achieve the desired improvement of symptoms.

[0129] In other embodiments, pharmaceutical compositions were provided comprising a compound of formula I of the present invention (including the compounds of formula IIa, IIb, III, and IV described herein) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereon, and a pharmaceutically acceptable carrier.

[0130] Other embodiments of the present invention relate to pharmaceutical compositions effective for the treatment of cancer, comprising a compound of formula I, IIa, IIb, III, or IV of the present invention as a CHK1 inhibitor, or a pharmaceutically acceptable salt thereof, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug, and at least one known anticancer agent or a pharmaceutically acceptable salt thereof. The at least one known anticancer agent or a pharmaceutically acceptable salt thereof includes other anticancer agents related to the mechanisms of DNA damage and repair, such as the PARP inhibitors olaparib, niraparib, lucaparib, talazoparib, and senaparib; the HDAC inhibitors Volinota, Romididesin, Papiseta, and Bailesta; and others. The at least one known anticancer agent or a pharmaceutically acceptable salt thereof also includes other anticancer agents related to cell division checkpoints, such as CDK4 / 6 inhibitors, e.g., palbociclib and ATM / ATR inhibitors.Other known anticancer agents that can be used in combination anticancer therapy include alkylating agents, e.g., busulfan, melphalan, chloroambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin and carboplatin; topoisomerase I inhibitors, e.g., camptothecin, irinotecan and topotecan; and topoisomerase II inhibitors, e.g., doxorubicin, epirubicin, and Clasinomycin, mitoxantrone, eriptinium and etoposide; RNA / DNA antimetabolites, e.g., 5-azacitidine, gemcitabine, 5-fluorouracil, capecitabine and methotrexate; DNA antimetabolites, e.g., 5-fluoro-2'-deoxyuridine, fludarabine, nerarabine, cytarabine, pralatrexate, pemetrexed, hydroxycarbamide and thioguanine; mitotic inhibitors, e.g., co Ruchtine, vinblastine, vincristine, vinorelbine, paclitaxel, isabepylone, cabazitaxel and docetaxel; antibodies, e.g., mAbs, panitumumab, nesitumumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab, tocitumomab, brentuximab, daratum This includes, but is not limited to, mab, elotuzumab, T-DM1, ofatumumab, dinutuximab, blinatumomab, ipilimumab, avastin, herceptin, mabusella, imatinib, gefitinib, erlotinib, osimertinib, afatinib, ceritinib, alectinib, crizotinib, erlotinib, lapatinib, sorafenib, snitinib, nilotinib, dasatinib, pazopanib, tricel, and everolimus. Other known anticancer agents that can be used in combination anticancer therapy include tamoxifen, letrozole, fulvestrant, mitogwazon, octreotide, retinoic acid, arsenic, zoledronic acid, bortezomib, carfilzomib, ixazomib, bismodegib, sonidecib, denosumab, thalidomide, lenalidomide, venetoclax, aldezleukin (recombinant human interleukin-2), and cypucel-T (prostate cancer treatment vaccine).

[0131] In carrying out the method of the present invention, one or more compounds of the present invention may be administered together with at least one known anticancer agent in a single pharmaceutical composition. Alternatively, one or more compounds of the present invention may be administered separately from at least one known anticancer agent. In one embodiment, one or more compounds of the present invention and at least one known anticancer agent are administered substantially simultaneously, i.e., all one or more compounds or agents are administered simultaneously or sequentially so that one or more compounds or agents reach a therapeutic concentration in the blood at the same time. In another embodiment, one or more compounds of the present invention and at least one known anticancer agent are administered according to individual dosing regimens so that one or more compounds reach a therapeutic concentration in the blood.

[0132] Another embodiment of the present invention relates to a bioconjugate comprising the compounds of the present invention and functioning as a kinase inhibitor effective in inhibiting tumors. The bioconjugate of the present invention comprises or consists of one or more of the compounds of the present invention and at least one known therapeutically useful antibody, such as trastuzumab or rituximab, or a growth factor, such as EGF or FGF, or a cytokine, such as IL-2 or IL-4, or any molecule that can bind to the cell surface. The antibody and other molecules can deliver the one or more compounds described herein to a target, thus becoming an effective anticancer agent. The bioconjugate can also enhance the anticancer effect of therapeutically useful antibodies, such as trastuzumab or rituximab.

[0133] Other embodiments of the present invention relate to pharmaceutical compositions effective for inhibiting tumors in combination with radiotherapy, comprising CHK1 inhibitors of formulas I, IIa, IIb, III, or IV or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates, or prodrugs thereof. In these embodiments, one or more compounds of the present invention can be administered concurrently with or at different times from radiotherapy.

[0134] Other embodiments of the present invention relate to pharmaceutical compositions effective for the postoperative treatment of cancer, comprising CHK1 inhibitors of formulas I, IIa, IIb, III, or IV or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates, or prodrugs thereof. The present invention also relates to a method for treating mammalian cancer with the pharmaceutical compositions of the present invention after surgical removal of the tumor.

[0135] The pharmaceutical compositions of the present invention encompass all pharmaceutical formulations containing one or more compounds of the present invention in amounts effective for achieving their intended use. Since the demands vary, those skilled in the art can determine the optimal amount of each component in the pharmaceutical formulation. Typically, a compound or a pharmaceutically acceptable salt thereof can be orally administered to a mammal daily at a dose of about 0.0025–50 mg per kg of body weight. Preferably, it is administered orally at a dose of about 0.01 mg / kg to about 10 mg / kg of body weight. If a known anticancer agent is also administered, it is administered in an amount effective for achieving its intended use. The optimal amount of such a known anticancer agent is well known to those skilled in the art.

[0136] A unit oral dose may contain one or more compounds of the present invention in an amount of about 0.01 to about 50 mg, preferably about 0.1 to about 10 mg. A unit dose can be administered once or more times per day in the form of one or more tablets, each tablet containing about 0.1 to about 50 mg, preferably about 0.25 to 10 mg, of one or more compounds of the present invention or their solvates.

[0137] In topical formulations, one or more compounds of the present invention may be present at a concentration of about 0.01 to 100 mg per gram of carrier.

[0138] The compounds of the present invention can be administered as untreated chemicals. Alternatively, one or more compounds of the present invention may be administered as part of a suitable pharmaceutical preparation comprising a pharmaceutically acceptable carrier (including excipients and adjuvants). The pharmaceutically acceptable carrier facilitates the preparation of a pharmaceutically acceptable preparation from one or more compounds. Preferably, pharmaceutical formulations, particularly oral formulations, and those used for preferred routes of administration (e.g., tablets, lozenges, and capsules), as well as solutions suitable for injection or oral administration, comprise about 0.01% to 99%, preferably about 0.25% to 75%, of one or more active compounds and one or more excipients.

[0139] Furthermore, the scope of the present invention includes non-toxic, pharmaceutically acceptable salts of one or more compounds of the present invention. Acid addition salts are formed by mixing a solution of one or more compounds of the present invention with a solution of a pharmaceutically acceptable, non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, or oxalic acid. Base addition salts are formed by mixing a solution of one or more compounds of the present invention with a solution of a pharmaceutically acceptable, non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, tris(hydroxymethyl)aminomethane, or N-methylglucamine.

[0140] The pharmaceutical formulations of the present invention can be administered to any mammal, insofar as the therapeutic effect of one or more of the compounds of the present invention is obtained. The most important of these mammals are humans and veterinary animals, but the present invention is not intended to be limited to them.

[0141] The pharmaceutical formulations of the present invention can be administered by any means, provided that their intended use is achieved. For example, administration can be carried out parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, percutaneously, buccally, intrathecally, intracranially, intranasally, or via local routes. Alternatively or additionally, administration can be carried out via oral routes. The dosage administered depends on the age, health, and weight of the subject, concomitant therapies, frequency of treatment, and desired therapeutic effect.

[0142] The pharmaceutical formulations of the present invention can be manufactured by known methods, for example, by conventional mixing, granulation, sugar coating, dissolution, or freeze-drying. Pharmaceutical formulations for oral use are obtained by combining one or more active compounds with one or more solid excipients, grinding the resulting mixture as needed, adding appropriate auxiliary agents as required, and processing the granular mixture to obtain tablets or lozenge cores.

[0143] Suitable excipients include, in particular, fillers such as sugars, e.g., lactose or sucrose, mannitol or sorbitol; cellulose preparations and / or calcium phosphate, e.g., tricalcium phosphate or calcium hydrogen phosphate; binders such as starch pastes containing corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone. Disintegrants such as the above starches and carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, or alginic acid or its salts (e.g., sodium alginate) may be added as needed. Auxiliaries include, in particular, flow regulators and lubricants such as silica, talc, stearic acid or its salts, e.g., magnesium stearate or calcium stearate, and / or polyethylene glycol. If necessary, the lozenge core may be coated with gastric juice. For this purpose, a concentrated sugar solution may be used that may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide, a lacquer solution and a suitable organic solvent or solvent mixture. To produce a coating against gastric juice, a suitable cellulose preparation solution such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate is used. The tablet or lozenge coating may be supplemented with dyes or pigments, for example, a combination for recognizing or characterizing the dose of one or more active compounds.

[0144] Other pharmaceutical formulations for oral use include push-fit capsules made of gelatin, and soft-seal capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Push-fit capsules may contain one or more active compounds in granular form, which can be mixed with a filler such as lactose; a binder such as starch; and / or a lubricant such as talc or magnesium stearate; and a stabilizer. In soft capsules, one or more active compounds are preferably dissolved or suspended in a suitable liquid such as fatty oil or liquid paraffin, to which a stabilizer can be added.

[0145] Formulations suitable for parenteral administration include aqueous solutions of the active compound, such as aqueous solutions of water-soluble salts and alkaline solutions. Furthermore, suspensions of the active compound can be administered as suitable oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides, or polyethylene glycol-400, or cremophores, or cyclodextrins. Aqueous injection suspensions may also contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, and / or dextran. Suspension stabilizers may also be included as needed.

[0146] According to one aspect of the present invention, the compound of the present invention is provided as a topical parenteral formulation and is used for the treatment of skin cancer.

[0147] The topical formulations of the present invention can be formulated as oils, creams, lotions, ointments, etc., with a suitable carrier. Suitable carriers include vegetable oils or mineral oils, white petrolatum (white soft paraffin), branched oils and fats, animal fats and high molecular weight alcohols (C 12It includes (larger than) a carrier. In a preferred carrier, the active ingredient is soluble. It may also include emulsifiers, stabilizers, humectants and antioxidants, as well as agents that provide color or fragrance as needed. Furthermore, these topical formulations may include transdermal penetration enhancers. Examples of such enhancers include U.S. Patent Nos. 3,989,816 and 4,444,762.

[0148] The cream is preferably formulated from a mixture of mineral oil, self-emulsifying beeswax, and water, and mixed with an active ingredient dissolved in a small amount of oil, such as almond oil. A typical example of such a cream contains about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil, and about 1 part almond oil.

[0149] The ointment can be prepared by mixing a solution of one or more active ingredients in a vegetable oil (e.g., almond oil) with warm, soft paraffin and then cooling the mixture. A typical example of such an ointment may contain about 30% by weight of almond oil and about 70% by weight of white ointment.

[0150] Furthermore, the present invention relates to the application of the compounds of the present invention in the manufacture of pharmaceuticals for the treatment of diseases, disorders, and clinical symptoms associated with continuous activation of CHK1 or high internal DNA damage or injury during DNA replication. These pharmaceuticals may include the above-mentioned pharmaceutical compositions.

[0151] The following examples illustrate, but do not limit, the methods and preparations of the present invention. Other appropriate modifications and adjustments of various conditions and parameters that are commonly encountered in clinical practice and are apparent to those skilled in the art are included in the spirit and scope of the present invention. [Examples]

[0152] General Overview All reagents meet commercial quality standards. Solvents were dried and purified using standard methods. Mass spectrometry was recorded using a Platform II (Agilent 6110) single quadrupole mass spectrometer with an electrospray interface. 1 ¹H NMR spectra were recorded at 400 MHz using a Brucker Ascend 400 instrument. Chemical shifts were recorded in ppm from low magnetic field relative to internal TMS (0.00 ppm), and J-bond constants were recorded in Hertz (Hz). The optical purity of compound samples was analyzed using a Shimazu LC-30ADsf.

[0153] Example 1 (S)-5-((5-(2-Methoxy-6-(Morpholin-2-ylmethoxy)phenyl)-1H-Pyrazole-3-yl)amino)pyrazine-2-carbonitrile

[0154] a) (2E)-3-(dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)-2-propenyl-1-one: A mixture of 1-(2-hydroxy-6-methoxyphenyl)-1-ethanone (25 g, 150.4 mmol) and N,N-dimethylformamide dimethylacetal (DMF-DMA, 80.6 mL, 676.1 mmol) was stirred at 110 °C for 1 hour. The reaction solution was quenched with water (100 mL), filtered, and the solid was washed with water (100 mL x 3) to obtain the target product (30.5 g, yield 91%, yellow solid). MS (ESI, m / z): 222 [M+H] + .

[0155] b) 3-Methoxy-2-(1,2-oxazole-5-yl)phenol: An ethanol solution of a mixture of (2E)-3-(dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)-2-propenyl-1-one (8.2 g, 37.1 mmol) and hydroxy-l-amine hydrochloride (2.3 g, 55.5 mmol) was stirred at 70°C under N2 protection for 1 hour. The reaction solution was quenched with water (100 mL), filtered, and the solid was washed with water (100 × mL) to obtain the target product (6.8 g, yield 95%, yellow solid). MS (ESI, m / z): 192 [M + H]+ .

[0156] c) tert-butyl(2S)-2-[3-methoxy-2-(1,2-oxazole-5-yl)phenoxymethyl]morpholine-4-carboxylate: At 0°C under N2 protection, a solution of triphenylphosphine (PPh3, 5.5g, 20.9 mmol) and diisopropyl azodicarboxylate (DIAD, 4.2g, 20.9 mmol) in tetrahydrofuran (30 mL) was stirred for 30 minutes. Next, at 0°C, 3-methoxy-2-(1,2-oxazole-5-yl)phenol (2.0g, 10.5 mmol) and tert-butyl(2S)-2-(hydroxymethyl)morpholine-4-carboxylate (2.7g, 12.6 mmol) were added to the reaction. The reaction mixture was stirred at room temperature for 16 hours. The reaction solution was quenched with water (100 mL) and extracted with ethyl acetate (80 mL x 3). The organic phases were combined, washed with saturated brine (40 mL x 2), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. This product was then purified by silica gel column chromatography (eluting with ethyl acetate (1-50%) petroleum ether solution) to obtain the target product (1.5 g, 36%, grayish-white solid). MS (ESI, m / z): 391 [M+H] + .

[0157] d) tert-butyl(2S)-2-[2-(2-cyanoacetyl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate: At room temperature, a mixture of tert-butyl(2S)-2-[3-methoxy-2-(1,2-oxazole-5-yl)phenoxymethyl]morpholine-4-carboxylate (1.50 g, 3.8 mmol) and potassium hydroxide (0.43 g, 7.7 mmol) was stirred in ethanol (15 mL) and water (5 mL) for 16 hours. The reaction solution was extracted with ethyl acetate (80 mL x 3), the organic phases were combined, washed with saturated brine (40 mL x 2), and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by silica gel column chromatography (eluting with ethyl acetate (1-50%) petroleum ether solution) to obtain the target product (648 mg, yield 65%, grayish-white solid). MS(ESI, m / z):391[M+H] + .

[0158] e) A mixture of tert-butyl(2S)-2-[2-(5-amino-2H-pyrazole-3-yl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate (648 mg, 1.7 mmol) and hydrazine hydrate (0.35 mL, 2.5 mmol, 35%) was stirred in tetrahydrofuran (1 mL), water (1 mL), and methanol (2 mL), and acetic acid (0.10 mL, 1.58 mmol) was added. The reaction mixture was stirred at 120 °C for 3 hours, and after cooling to room temperature, it was diluted with water (50 mL) and extracted with ethyl acetate (80 mL x 3). The organic phases were combined, washed with saturated brine (40 mL x 2), and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated under reduced pressure to obtain the crude product, and then purified by silica gel column chromatography (eluting with methanol (1-10%) dichloromethane solution) to obtain the target product (512 mg, yield 76%, grayish-white solid). MS (ESI, m / z): 405 [M+H] + .

[0159] f) tert-butyl(2S)-2-(2-[5-[(5-cyanopyrazine-2-yl)amino]-2H-pyrazole-3-yl]-3-methoxyphenoxy)morpholine-4-carboxylate: A mixture of tert-butyl(2S)-2-[2-(5-amino-2H-pyrazole-3-yl)-3-methoxyphenoxymethyl]morpholine-4-carboxylate (180 mg, 0.45 mmol) and 5-chloropyrazine-2-carbonitrile (71 mg, 0.51 mmol) was dissolved in dimethyl sulfoxide (4 mL), to which N-ethylmorpholine (48 μL, 0.534 mmol) was added. The reaction mixture was stirred at 80°C under N2 protection for 3 hours, and the resulting reaction solution was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (40 mL x 2), and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated under reduced pressure to obtain the crude product, and then purified by silica gel column chromatography (eluting with methanol (1-10%) dichloromethane solution) to obtain the target product (154 mg, yield 68%, grayish-white solid). MS (ESI, m / z): 508 [M+H] + .

[0160] g)(S)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile: At room temperature, a solution of tert-butyl(2S)-2-(2-[5-[(5-cyano-pyrazine-2-yl)amino]-2H-pyrazole-3-yl]-3-methoxyphenoxy)morpholine-4-carboxylate (120 mg, 0.236 mmol) in dichloromethane (1 mL) and trifluoroacetic acid (0.2 mL) was stirred for 1 hour. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was then purified by reverse-phase chromatography (XBridge Shield RP18 OBD column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mM NH4HCO3), mobile phase B: acetonitrile; UV 254 nm) to obtain the target compound (30 mg, yield 31%, grayish-white solid).

[0161] Example 2 (S)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)picolinonitrile The compounds in this example were prepared in the same manner as in Example 1.

[0162] Example 3 (R)-5-((5-(2-Methoxy-6-(Morpholin-2-ylmethoxy)phenyl)-1H-Pyrazole-3-yl)amino)pyrazine-2-carbonitrile

[0163] a) 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)ethane-1-one:1-(2-hydroxy-6-methoxyphenyl)ethenone (2 g, 12.04 mmol) in DMF (16 mL) was mixed with K2CO3 (4.16 g, 30.09 mmol) and the mixture was stirred at 25°C for 30 minutes. Next, p-methoxybenzyl chloride (PMBCl, 2.26 g, 14.44 mmol, 1.97 mL) was added dropwise to the above reaction mixture and the reaction mixture was stirred at 25°C for 12 hours. Water (80 mL) was added to quench the reaction, the mixture was extracted with EA (80 mL x 3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was pulped in PE (10 mL) at 30°C for 10 minutes to obtain the target crude product (3.12 g, yellow solid, yield 90.4%). 1 H NMR (400MHz, CDCl3): δ7.31-7.29(m, 2H), 7.24(t, J=8.4Hz, 1H), 6.91-6.88(m, 2H), 6.6 1(d, J=4.4Hz, 1H), 6.57(d, J=4.4Hz, 1H), 5.02(s, 2H), 3.82-3.81(m, 6H), 2.47(s, 3H).

[0164] b) 1-(2-Methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-3,3-bis(methylsulfonyl)-2-propen-1-one: Under nitrogen protection, 1-(2-methoxy-6-((4-methoxybenzyl)oxy)phenyl)ethan-1-one (1 g, 3.49 mmol) was added to anhydrous DMSO (2 mL) of a mixture of t-BuOLi (615.11 mg, 7.68 mmol, 692.70 μL). The internal temperature was maintained below 30 °C, and the resulting mixture was stirred for 30 minutes. CS2 (319.11 mg, 4.19 mmol, 253.26 μL) was slowly added. The mixture was stirred at 30 °C for 1 hour, MeI (991.46 mg, 6.99 mmol, 434.85 μL) was slowly added, and the internal temperature was maintained below 30 °C. The resulting mixture was stirred at 30 °C for 1.5 hours. Water (80 mL) was added to dilute the mixture, and the mixture was extracted with EA (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. At 30 °C, the resulting residue was pulped in EA for 15 minutes and washed with MTBE (10 mL × 3) to obtain the target crude product (1.04 g, yellow solid, yield 76.5%). MS (ESI, m / z): 391.0 [M+H] + . 1 H NMR (400 MHz, CDCl3): δ 7.31 - 7.29 (m, 2H), 7.22 (t, J = 8.4 Hz, 1H), 6.88 - 6.86 (m, 2H), 6.59 (t, J = 8.8 Hz, 2H), 6.26 (s, 1H), 5.03 (s, 1H), 3.81 - 3.75 (m, 6H), 2.51 (s, 3H), 2.31 (s, 3H).

[0165] c) A mixed solution of 5-(((E)-3-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1-methylsulfonyl-3-oxo-1-propenyl)amino)pyrazine-2-carbonitrile:NaH (46.09 mg, 1.15 mmol, 60% purity) and THF (3 mL) was cooled to 5-15°C, and the temperature was maintained at 10°C to control hydrogen release. 5-aminopyrazine-2-carbonitrile (110.73 mg, 921.86 mL) was added in four portions, removing foam between additions. The mixture was stirred for 90 minutes, during which time the temperature was raised to 15°C. To control foaming, 1-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-3,3-bis(methylsulfonyl)-2-propen-1-one (300 mg, 768.22 umol) was added to the above reaction mixture in several portions. The mixture was stirred for 15 minutes and then heated until refluxed. o The reaction was carried out in 1C for 2 hours. The reaction mixture was poured into cold water (40 mL) and extracted with EA (40 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. At 30°C, the resulting residue was recrystallized in EA (10 mL) to obtain the target crude product (231 mg, yellow solid, yield 65.1%). MS (ESI, m / z): 463.1 [M+H] + .

[0166] d) 5-((5-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile:5-(((E)-3-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1-methylsulfonyl-3-oxo-1-propenyl)amino)pyrazine-2-carbonitrile (230 mg, 497.28 umol), AcOH (86.95 mg, 1.45 mmol, 82.81 uL), and EtOH (5.5 mL). The atmosphere in the reaction flask was replaced three times with nitrogen. Next, under nitrogen protection, N2H4·H2O (49.31 mg, 965.32 umol, 47.87 uL, purity 98%) was added dropwise, and the resulting mixture was stirred at 65°C for 1 hour. The reaction mixture was filtered to obtain a filter cake. The filter cake was washed with EtOH (5 mL x 3) to obtain the target crude product (197 mg, yellow solid, yield 85.7%). MS (ESI, m / z): 429.1 [M+H] + .

[0167] e) 5-((5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride dihydrochloride: 5-((5-(2-methoxy-6-((4-methoxyphenyl)methoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride (197 mg, 459.80 umol) was dissolved in dioxane (6 mL) and then HCl-dioxane solution (4 M, 5.75 mL) was added. The resulting mixture was stirred at 25 °C for 10 hours and then concentrated under reduced pressure to obtain the target crude product (161 mg, yellow solid, yield 95.3%). MS (ESI, m / z): 309.1 [M + H] + .

[0168] f)tert-butyl(2R)-2-((2-[3-((5-cyanopyrazine-2-yl)amino)-1H-pyrazole-5-yl]-3-methoxyphenoxy)methyl]morpholine-4-carboxylate: At -5°C, TEA (105.69 mg, 1.04 mmol, 145.38 μL) was added to a solution of 5-((5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride dihydrochloride (161 mg, 422.33 μL) in THF (2 ml). The resulting mixture was stirred at -5°C for 30 minutes to obtain mixture A. At 25°C, triphenyl phosphate (342.44 mg, 1.31 mmol) was dissolved in THF (2 ml). The resulting colorless, transparent solution was cooled to -5°C in an acetone / ice bath, and diisopropyl azo was added to the solution. Dicarboxylate (DIAD, 253.44 mg, 1.25 mmol, 243.69 μL) was added dropwise over 20 minutes, maintaining the temperature below 10°C. The resulting viscous white pulp was cooled again to -5-0°C, and a solution of tert-butyl(2R)-2-(hydroxymethyl)morpholine-4-carboxylate (283.65 mg, 1.31 mmol) in THF (2 mL) was added. The mixture was stirred at -5°C for 20 minutes to obtain mixture B. Mixture A was added dropwise to mixture B at -5°C and stirred at 50°C for 30 minutes. The residue obtained from the reaction mixture by vacuum concentration was purified by preparative thin-film chromatography (SiO2, PE:EA=1:1), followed by separation and purification by preparative column chromatography to obtain the target crude product (12 mg, yellow solid, yield 5.6%). MS (ESI, m / z): 508.2 [M+H] + .

[0169] g)(R)-5-((5-(2-methoxy-6-(morpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile: At 0°C, tert-butyl(2R)-2-((2-[3-[((5-cyano-pyrazine-2-yl)amino)-1H-pyrazole-5-yl]-3-methoxyphenoxy)methyl]morpholine-4-carboxylate (12 mg, 23.64 umol) was dissolved in DCM (2.5 mL) and TFA (808.77 mg, 7.09 mmol, 525.17 μL) was added. The resulting mixture was stirred at 20°C for 1 hour, then concentrated under reduced pressure to obtain the crude product, which was then separated and purified by preparative chromatography column to obtain the target compound (7.59 mg, 14.05 umol, white solid, yield 59.44%).

[0170] The compound of Example 4 was synthesized from a DMF solution of the compound of Example 1 and MeI in the presence of K2CO3. This compound can also be synthesized by other methods known to those skilled in the art.

[0171] Examples 5-50 were prepared by the same synthetic method as in Example 1 or 2. These compounds can also be synthesized by other methods known to those skilled in the art.

[0172] [Table A]

[0173] [Table B]

[0174] [Table C]

[0175] [Table D]

[0176] Table E

[0177] Table F

[0178]

Table G

[0179] Table H

[0180] Table I

[0181] Table J

[0182]

Table K

[0183]

Table L

[0184]

Table M

[0185]

Table N

[0186]

Table O

[0187]

Table P

[0188]

Table Q

[0189] Example 51 (S)-5-((5-(2-Methoxy-6-(piperidin-3-ylmethoxy)phenyl)-4-methyl-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile

[0190]

Chemical formula

[0191] a) tert-Butyl (3S)-3-[[2-(3-amino-4-bromo-1H-pyrazol-5-yl)-3-methoxyphenoxy]methyl]piperidine-1-carboxylate: NBS (778.29 mg, 4.37 mmol) was added to a solution of tert-butyl (3S)-3-[[2-(3-amino-1H-pyrazol-5-yl)-3-methoxyphenoxy]methyl]piperidine-1-carboxylate (1.6 g, 3.98 mmol, this compound was prepared in the same manner as in Example 1e) in ACN (32 mL). The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched by the addition of saturated NaHCO3 solution (150 mL) at 0 °C and then extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with brine (50 mL × 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product (1.9 g) as a red oil. MS (ESI, m / z): 481.1 [M + H] + .

[0192] b) tert-Butyl (3S)-3-[[2-(3-amino-4-methyl-1H-pyrazol-5-yl)-3-methoxyphenoxy]methyl]piperidine-1-carboxylate: A solution of tert-butyl (3S)-3-[[2-(3-amino-4-bromo-1H-pyrazol-5-yl)-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate (500 mg, 1.04 mmol) and methylboronic acid (373.05 mg, 6.23 mmol) in dioxane (50 mL) was added with chloro(2-dicyclohexylphosphino-2’,4’,6’-triisopropyl-1,1’-biphenyl)[2-(2’-amino-1,1’-biphenyl)]palladium(II) (XPhos Pd G2, 163.45 mg, 207.74 μmol), di-tert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (176.43 mg, 415.47 μmol) and K2CO3 (861.31 mg, 6.23 mmol). The mixture was stirred at 100 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by reverse-phase HPLC (0.1% FA conditions) to obtain a mixture of the desired product and a by-product (tert-butyl (3S)-3-[[2-(3-amino-1H-pyrazol-5-yl)-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate) (1,80 mg) as a brown solid. MS (ESI, m / z): 417.2 [M+H] + .

[0193] c) tert-butyl(3S)-3-[[2-[3-[(5-cyanopyrazine-2-yl)amino]-4-methyl-1H-pyrazole-5-yl]-3-methoxyphenoxy]methyl]piperidine-1-carboxylate: To a solution of the above mixture (Example 51b, 432.16 μmol, 180 mg) in DMSO (5 mL), 5-chloropyrazine-2-carbonitride (180.91 mg, 1.30 mmol) and DIPEA (167.56 mg, 1.30 mmol) were added. The mixture was stirred at 90°C for 16 hours. The reaction mixture was diluted with H2O (30 mL), extracted with ethyl acetate (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. This residue was purified by reverse-phase HPLC (0.1% FA conditions), and further purified by prep-HPLC (column: Welch Ultimate XB-CN 250 x 70 x 10 μm; mobile phase: [hexane-EtOH (0.1% NH3·H2O)]; B%: 20%-60%, 15 minutes) to obtain the target product (50 mg, yield 22.27%) as a yellow oil. MS (ESI, m / z): 520.2 [M+H] + .

[0194] d) (S)-5-((5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-4-methyl-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride:tert-butyl(3S)-3-[[2-[3-[(5-cyanopyrazine-2-yl)amino]-4-methyl-1H-pyrazole-5-yl]-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate (50 mg, 96.23 μmol) in DCM (1 mL) was mixed with TFA (274.30 mg, 2.41 mmol, 178.12 μL). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the residue, which was purified by prep-HPLC (column: Phenomenex luna C18 150×25mm×10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 8%-38%, 10 minutes) to obtain the target compound (24.63 mg, 51.53 μmol, yield 53.55%, purity 97.40%) as a yellow solid. MS (ESI, m / z): 420.2 [M+H] + .1 H NMR (400MHz, MeOD): δ8.46(d, J=1.2Hz, 1H), 8.32(d, J=1.2Hz, 1H), 7.41(t, J=8.4 Hz, 1H), 6.77(dd, J=8.4Hz, 17.6Hz, 2H), 4.02-3.97(m, 1H), 3.89-3.85(m, 1H), 3. 79(s, 3H), 3.27-3.25(m, 1H), 2.83-2.75(m, 1H), 2.67(t, J=12.0Hz, 1H), 2.17-2. 08(m, 1H), 1.89-1.83(m, 2H), 1.81(s, 3H), 1.75-1.63(m, 1H), 1.41-1.29(m, 2H). SFC:ee%:100%.

[0195] Example 52 (S)-5-((4-bromo-5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile [ka]

[0196] a) To a DMSO (5 mL) solution of tert-butyl(3S)-3-[[2-[3-[(5-cyanopyrazine-2-yl)amino]-1H-pyrazole-5-yl]-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate (Example 51c, 500 mg, 1.24 mmol), DIPEA (481.66 mg, 3.73 mmol, 649.13 μL) and 5-chloropyrazine-2-carbonitrile (520.05 mg, 3.73 mmol) were added. The mixture was stirred at 90 °C for 16 hours. The reaction mixture was diluted with H2O (30 mL), extracted with ethyl acetate (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was purified by reverse-phase HPLC (0.1% FA conditions) to obtain the residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 250 × 50 mm × 15 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 55%-85%, 10 minutes) to obtain the target product (330 mg, 652.73 μmol, yield 52.54%) as a brown solid. MS (ESI, m / z): 506.3 [M+H] + .

[0197] b) tert-butyl(3S)-3-[[2-[4-bromo-3-[(5-cyanopyrazine-2-yl)amino]-1H-pyrazole-5-yl]-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate (280 mg, 553.83 μmol) was dissolved in ACN (10 mL) and NBS (108.43 mg, 609.22 μmol) was added. The mixture was stirred at 25 °C for 12 hours. The pH of the mixture was adjusted to 7 with NaHCO3 solution (10 mL). The mixture was extracted with ethyl acetate (50 mL x 3), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was purified by reverse-phase HPLC (0.1% FA conditions) to obtain the target product (138 mg, yield 36.2%) as a yellow oil. MS (ESI, m / z): 584.0 [M+H] + .

[0198] c) (S)-5-((4-bromo-5-(2-methoxy-6-(piperidine-3-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitride:tert-butyl(3S)-3-[[2-[4-bromo-3-[(5-cyanopyrazine-2-yl)amino]-1H-pyrazole-5-yl]-3-methoxy-phenoxy]methyl]piperidine-1-carboxylate (138 mg, 236.11 μmol) in a 2 mL solution of DCM, to which TFA (673.06 mg, 5.90 mmol, 437.05 μL) was added, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the residue, which was purified by prep-HPLC (column: Phenomenex luna C18 150×25mm×10um; mobile phase: [water (0.225% FA)-ACN]; B%: 10%-43%, 11 minutes) to obtain the target compound (81.54 mg, 151.62 μmol, yield 64.21%) as a pale yellow solid. MS (ESI, m / z): 484.0[M+H]+. 1H NMR (400MHz, MeOD): δ8.50(d, J=1.2Hz, 1H), 8.44(d, J=1.2Hz, 1H), 7.44(t, J=8.4Hz, 1H), 6.80-6.74(m, 2H), 4.04-4.01(m, 1H), 3.91-3.87(m, 1H), 3.80(s, 3H), 3.37-3.34(m, 2H), 2.84-2.80(m, 1H), 2.75-2.69(m, 1H), 2. 17-2.16(m, 1H), 1.94-1.86(m, 2H), 1.75-1.66(m, 1H), 1.40-1.39(m, 1H). SFC:ee%:100%.

[0199] Examples 53-75 were prepared by the same synthetic method as in Example 1 or 2. These compounds can also be synthesized by other methods known to those skilled in the art.

[0200] [Table R]

[0201] [Table S]

[0202]

Table T

[0203]

Table U

[0204]

Table V

[0205]

Table W

[0206] Example 76 (S)-5-((5-(2-Methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(2-Methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile

[0207] a) tert-butyl-2-[[2-[3-[(5-cyanopyrazine-2-yl)amino]-1H-pyrazole-5-yl]-3-methoxyphenoxy]methyl]thiomorpholine-4-carboxylate: To a toluene (16 mL) solution mixture of tert-butyl-2-(hydroxymethyl)thiomorpholine-4-carboxylate (340.57 mg, 1.46 mmol, 1.5 eq), 5-[[5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazole-3-yl]amino]pyrazine-2-carbonitrile (Example 3e, 300 mg, 973.10 μmol) was added, and then 2-(tributylphosphanylidene)acetonitrile (704.57 mg, 2.92 mmol) was added. The mixture was heated at 90°C for 4 hours. The reaction mixture was concentrated under reduced pressure to obtain the residue, which was purified by prep-HPLC to obtain the target product (83 mg, crude, 16.3% yield) as a yellow oil. MS (ESI, m / z): 524.3 [M+H] + .

[0208] b) A mixture of 5-[[5-[2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl]-1H-pyrazole-3-yl]amino]pyrazine-2-carbonitride:tert-butyl-2-[[2-[3-[(5-cyanopyrazine-2-yl)amino]-1H-pyrazole-5-yl]-3-methoxy-phenoxy]methyl]thiomorpholine-4-carboxylate (81 mg, 154.70 μmol) in HCOOH (1 mL) solution was degassed, purged with N2 three times, and then stirred at 25°C under an N2 atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain the residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150×25mm×10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 9%-39%, 10 minutes) to obtain the target product (65 mg, crude, 99.2% yield) as a yellow solid. MS (ESI, m / z): 524.3 [M+H] + . 1H NMR (400MHz, DMSO-d6): δ8.47(s, 2H), 6.99-6.90(m, 1H), 6.61(d, J=10.4Hz, 2H), 4.15-4.09(m, 2H), 3.89(s, 3H) ), 3.69-3.64(m, 2H), 3.13(s, 1H), 2.85-2.71(m, 1H), 2.54-2.52(m, 1H), 1.82-1.81(m, 1H), 1.62-1.54(m, 2H).

[0209] c) (S)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(2-methoxy-6-(thiomorpholine-2-ylmethoxy)phenyl)-1H-pyrazole-3-yl)amino)pyrazine-2-carbonitrile: The above products were separated by SFC (column: DAIEL CHIRALPAK IG (250 mm × 30 mm, 10 μm); mobile phase: [0.1% NH3H2OMEOH]; B%: 70%-70%, 6.2; 60 minutes) to obtain two residues. Residue 1 was purified by prep-HPLC (column: Unisil 3-100 C18 Ultra 150×50mm×3μm; mobile phase: [water (0.225%FA)-ACN]; B%: 15%-35%, 10 minutes) to obtain one target compound (76-A, 17.42 mg, 39.50 μmol, yield 25.74%, purity 96.03%) as a pale yellow solid. Residue 2 was purified by prep-HPLC (column: Unisil 3-100 C18 Ultra 150×50mm×3μm; mobile phase: [water (0.225%FA)-ACN]; B%: 15%-35%, 10 minutes) to obtain another target compound (76-B, 12.15 mg, 27.50 μmol, yield 17.91%, purity 95.84%) as a pale yellow solid.

[0210] Examples 77-80 were prepared by the same synthetic method as in Example 1 or 2, and separated by the same method as in Example 76. These compounds can also be synthesized by other methods known to those skilled in the art.

[0211] [Table X]

[0212] [Table Y]

[0213] [Table Z]

[0214] Example 81 Confirmation of the inhibitory effect of compounds on CHK1 kinase CHK1 enzyme activity was measured using Promega's ADP-Glo™ kinase assay kit (#V9101) in a 384-well plate (Corning, #4512). 2 μL of kinase CHK1 (#V1941, Promega), 1 μL of the compound diluted in buffer, and 2 μL of ATP substrate were sequentially added to the 384-well plate (final CHK1 concentration 1 ng / well, ATP 10 μM). Positive control wells contained CHK1, ATP, and DMSO, while negative control wells contained ATP without the enzyme and DMSO. The mixtures were centrifuged at 1000 rpm for 1 minute and allowed to react in the dark at room temperature for 1 hour. Next, 5 μL of ADP-Glo ​​reagent was added to each well, and the mixtures were incubated at room temperature for 40 minutes. At the end of the incubation period, 10 μL of kinase detection reagent was added to each well, and the relative chemiluminescence (RLU) value was measured using Varioskan® Flash (Thermo). The following calculation was performed: Inhibition rate % = (RLU of positive control - RLU of compound) / (RLU of positive control - RLU of negative control) × 100. The data was analyzed with GraphPad Prism 6.0 and fitted with the equation of the curve: Y = lower part + (upper part - lower part) / (1 + 10^((LogIC) 50 -X)* Hill slope)), IC 50 The value was calculated.

[0215] Table 1 summarizes the inhibitory effects of compounds on CHK1 kinase activity at a concentration of 10 nM (Inh%).

[0216] [Table 1]

[0217] Table 2 shows CHK1 kinase activity (IC1). 50 The inhibitory effects of compounds on ) were summarized.

[0218] [Table 2]

[0219] Therefore, as confirmed by CHK1 kinase experiments, the compound of Example 1 and its analogues have a good inhibitory effect on CHK1 kinase.

[0220] Example 82 Confirmation of the inhibitory effect of compounds on the proliferation of human breast cancer cells HCC1806 using the MTT test. Newly revived HCC1806 cells (purchased from Guangzhou Genio) were cultured and passaged for at least three generations before use. For the experiment, the cells were used at 90% confluence. The cells were digested with trypsinase and centrifuged at 800 rpm for 5 minutes. The cell pellet was resuspended in fresh RPMI1640 medium and the cells were counted. The cells were seeded at 2000 cells / well in 96-well cell culture plates and cultured overnight at 37°C and 5% CO2. Stock solutions of the test substances (including the test compound and reference compound) were serially diluted to eight concentrations in a 1:3 ratio with DMSO. 5 μL of each serially diluted solution was added to 120 μL of medium (25-fold dilution) and mixed by shaking. The medium of the cells cultured overnight was replaced with 195 μL / well of fresh medium and 5 μL / well of diluted medium containing the test compound. The cell culture plates were returned to a 37°C, 5% CO2 incubator for 3 days. At the end of the treatment, cell viability was determined by MTT colorimetric analysis. The cell culture medium in each well was replaced with 100 μL / well of serum-free fresh medium containing MTT (0.5 mg / mL), and the culture was continued for another 4 hours. Next, the medium was discarded, 100 μL / well of DMSO was added, the plate was shaken in the dark for 10 minutes, and the absorbance was measured at wavelengths of 552 / 690 nm using a multifunction reader.

[0221] The data were analyzed using GraphPad Prism 6.0. The inhibitory effect of the compounds on cell proliferation was plotted based on cell viability relative to compound concentration. Cell viability % = (OD compound - OD background) / (OD DMSO -OD background) x 100. I C 50 The value is given by the sigmoid dose-response curve equation Y = 100 / (1 + 10^(LogC - LogIC) 50 It is fitted with )) and C is the concentration of the compound.

[0222] Table 3 shows the inhibitory effect of compounds on the proliferation of human breast cancer cells HCC1806 (IC). 50 ) was compiled.

[0223] [Table 3]

[0224] Therefore, as confirmed by the MTT test, the compound of Example 1 and its analogues have a good inhibitory effect on the proliferation of HCC1806 cells.

[0225] Example 83 Confirmation of the inhibitory effect of compounds on the proliferation of human pancreatic cancer cells SW1990 using the MTT test. Newly revived SW1990 cells (purchased from Shanghai Fuheng Biotechnology Co., Ltd.) were cultured and passed through at least three generations before use. For the experiment, the cells were used at approximately 90% confluence. The cells were digested with trypsinase and centrifuged at 800 rpm for 5 minutes. The cell pellet was resuspended in fresh DMEM medium and the cells were counted. The cells were seeded at 5000 cells / well in 96-well cell culture plates and cultured overnight at 37°C and 5% CO2. Stock solutions of the test substances (including the test compound and reference compound) were serially diluted to eight concentrations in a 1:3 ratio with DMSO. 5 μL of each serially diluted solution was added to 120 μL of medium (25-fold dilution) and mixed by shaking. The medium of the cells cultured overnight was replaced with 195 μL / well of fresh medium and 5 μL / well of diluted medium containing the test compound. The cell culture plates were returned to an incubator at 37°C and 5% CO2 for 5 days. At the end of treatment, cell viability was determined by MTT colorimetric analysis. The cell culture medium in each well was replaced with 100 μL / well of serum-free fresh medium containing MTT (0.5 mg / mL), and the culture was continued for another 4 hours. Next, the medium was discarded, and 100 μL / well of DMSO was added. The plate was shaken in the dark for 10 minutes, and the absorbance was measured at wavelengths of 552 / 690 nm using a multifunction reader.

[0226] The data were analyzed using GraphPad Prism 6.0. The inhibitory effect of the compounds on cell proliferation was plotted based on cell viability relative to compound concentration. Cell viability % = (OD compound - OD background) / (OD DMSO -OD background) x 100. I C 50 The value is given by the sigmoid dose-response curve equation Y = 100 / (1 + 10^(LogC - LogIC) 50It is fitted with )) and C is the concentration of the compound.

[0227] Table 4 shows the inhibitory effect of compounds on the proliferation of human pancreatic cancer cells SW1990 (IC). 50 ) was compiled.

[0228] [Table 4]

[0229] Therefore, as confirmed by the MTT test, the compound of Example 1 and its analogues have a good inhibitory effect on the proliferation of SW1990 cells.

[0230] Example 84 Determination of the inhibitory effect of the present invention compound on the proliferation of human colon cancer cells (LoVo) using the MTT test. Newly revived LoVo cells (purchased from Shanghai Cell Research Institute) were cultured and passaged for at least three generations before use. For the experiment, cells were used at 90% confluence. The cells were digested with trypsinase, centrifuged at 800 rpm for 5 minutes, and the supernatant was discarded. The cell pellet was resuspended in fresh RPMI1640 medium and counted. The cells were seeded at 5000 cells / well in 96-well cell culture plates and cultured overnight at 37°C and 5% CO2. Stock solutions of the test substances (including the test compound and reference compound) were serially diluted to eight concentrations in a 1:3 ratio with DMSO. 5 μL of each serially diluted solution was added to 120 μL of medium (25-fold dilution) and mixed by shaking. The medium of the cells cultured overnight was replaced with 195 μL / well of fresh medium and 5 μL / well of diluted medium containing the test compound. The cell culture plates were returned to an incubator at 37°C and 4% CO2 for 5 days. At the end of the treatment, cell viability was determined by MTT colorimetric analysis. The cell culture medium in each well was replaced with 100 μL / well of serum-free DMEM medium containing MTT (0.5 mg / mL), and the culture was continued for a further 4 hours. The medium was then discarded, and 100 μL / well of DMSO was added. The plates were shaken in the dark for 10 minutes, and the absorbance was measured at wavelengths of 552 / 690 nm using a multifunction reader.

[0231] The data were analyzed using GraphPad Prism 6.0. The inhibitory effect of the compounds on cell proliferation was plotted based on cell viability relative to compound concentration. Cell viability % = (OD compound - OD background) / (OD DMSO -OD background) x 100. I C 50 The value is given by the sigmoid dose-response curve equation Y = 100 / (1 + 10^(LogC - LogIC) 50 It is fitted with )) and C is the concentration of the compound.

[0232] Table 5 shows the inhibitory effect of compounds on the proliferation of human colon cancer cells LoVo (IC). 50 ) was compiled.

[0233] [Table 5]

[0234] Therefore, as confirmed by the MTT test, the compound of Example 1 and its analogues have a good inhibitory effect on the proliferation of LoVo cells.

[0235] Since the present invention has been fully described, it will be recognized by those skilled in the art that the same implementation can be carried out using various equivalent conditions, formulations, and other parameters without departing from the spirit or embodiments of the invention. All patents, applications, and publications cited herein are incorporated in their entirety by reference.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof, 【Chemistry 1】 A 0 , A 1 and A 2 are N and CR independently a Selected from the group consisting of: R 0 is selected from the group consisting of hydrogen, a cyano group, an alkyl group, an alkoxy group, and a carbonyl group, and the alkyl group, alkoxy group, and carbonyl group may be substituted; R 1 is selected from the group consisting of halogen, a hydroxy group, and an optionally substituted alkoxy group; R 2 -R 4 are independently selected from the group consisting of hydrogen, halogen, an alkyl group, an alkoxy group, a nitro group, a carbonyl group, and an acylamino group, and the alkyl group, alkoxy group, carbonyl group, and acylamino group may be substituted; R 5 is selected from the group consisting of hydrogen, an optionally substituted alkyl group, and an optionally substituted alkoxy group; R 6 is selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl groups; L is a bond, -C(R b ) 2 -, O, S or NR b is; Z is a bond or an alkylene group; Q is an optionally substituted heterocyclic group; R a is selected from the group consisting of H, optionally substituted alkyl groups and halogens; R b are independently selected from the group consisting of hydrogen and optionally substituted alkyl groups; compound.

2. A 0 and A 1 is N or CH; A 2 is N, CH or CCH 3 is; R 0 is a cyano group, C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 1 is a halogen, a hydroxy group, C 1 -C 3 Alkoxy group or halogenated C 1 -C 3 is an alkoxy group; R 2 -R 4 are independently hydrogen, halogen, C 1 -C 3 Alkyl group, C 1 -C 3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 5 is hydrogen; R 6 is hydrogen; L is C 1-3 Alkylene group, O, S or NR b and R b is preferably hydrogen or C 1-3 is an alkyl group; Z is C 1-3 an alkylene group, more preferably a methylene group; Q is an unsubstituted saturated 3- to 7-membered heterocyclic group or an optionally 1- to 2-substituted C 1-3 a saturated 3-7 membered heterocyclic group substituted by an alkyl group, wherein one or more substituents are at the ortho, meta and / or para positions, but not at the attachment position; The compound of claim 1.

3. the compound is a compound of Formula IIa, or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof; 【Chemistry 2】 R 0 is a cyano group, C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 1 is a halogen, a hydroxy group, C 1 -C 3 Alkoxy group or halogenated C 1 -C 3 is an alkoxy group; R 2 -R 4 are independently hydrogen, halogen, C 1 -C 3 Alkyl group, C 1 -C 3 Alkoxy group or halogenated C 1-3 is an alkyl group; L is C 1-3 Alkylene group, O, S or NR b and R b is hydrogen or C 1-3 is an alkyl group; Z is a bond or an alkylene group; Q is an unsubstituted heterocyclic group or a substituted heterocyclic group in which one or more substituents are not at the connecting position but at the ortho, meta and / or para positions relative to the connecting position; preferably, Q is an unsubstituted saturated 3-7 membered heterocyclic group or an optionally 1-2 substituted C 1-3 Preferably, Q is selected from the group consisting of: 【Transformation 3】 * indicates the point of attachment of the substituent to the remainder of the compound; The compound of claim 1.

4. the compound is a compound of Formula IIb, or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof; 【Chemistry 4】 R 0 is a cyano group, C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 1 is a halogen, a hydroxy group, C 1 -C 3 Alkoxy group or halogenated C 1 -C 3 is an alkoxy group; R 2 -R 4 are independently hydrogen, halogen, C 1 -C 3 Alkyl group, C 1 -C 3 Alkoxy groups and halogenated C 1-3 selected from the group consisting of alkyl groups; L is C 1-3 Alkylene group, O, S or NR b and R b is hydrogen or C 1-3 is an alkyl group; Q is an unsubstituted saturated 3- to 7-membered heterocyclic group or an optionally 1- to 2-substituted C 1-3 A saturated 3-7 membered heterocyclic group substituted with an alkyl group at the ortho, meta and / or para positions relative to the attachment position, but not at the attachment position; preferably, Q is selected from the group consisting of: 【Transformation 5】 * indicates the point of attachment of the substituent to the remainder of the compound; The compound of claim 1.

5. the compound is of formula III, or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof; 【Transformation 6】 R 1 is a halogen, a hydroxy group, C 1 -C 3 Alkoxy group or halogenated C 1 -C 3 is an alkoxy group; R 3 is hydrogen, halogen, C 1 -C 3 Alkyl group, C 1 -C 3 Alkoxy group or halogenated C 1-3 is an alkyl group; Q is an unsubstituted saturated 3- to 7-membered heterocyclic group or an optionally 1- to 2-substituted C 1-3 A saturated 3-7 membered heterocyclic group substituted with an alkyl group at the ortho, meta and / or para positions relative to the attachment position, but not at the attachment position; preferably, Q is selected from the group consisting of: 【Transformation 7】 * indicates the point of attachment of the substituent to the remainder of the compound; The compound of claim 1.

6. the compound is a compound of formula IV, or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate, or prodrug thereof: 【Transformation 8】 A 0 , A 1 , A 2 , R 0 -R 6 , L, and Z are defined in claim 1; A 3 is CH or N; Ring Q is a 3- to 7-membered heterocyclic group; R 7 is selected from the group consisting of halogen, a hydroxy group, an amino group, a carboxyl group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group; n is an integer selected from the group consisting of 0-3, preferably 0-2; The compound of claim 1.

7. A 0 and A 1 is N or CH; A 2 is N, CH or CCH 3 is; R 0 is a cyano group, C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 1 is a halogen, a hydroxy group, C 1 -C 3 Alkoxy group or halogenated C 1 -C 3 is an alkoxy group; R 2 -R 4 are independently hydrogen, halogen, C 1 -C 3 Alkyl group, C 1 -C 3 Alkoxy group or halogenated C 1-3 is an alkyl group; R 5 is hydrogen; R 6 is hydrogen; L is C 1-3 Alkylene group, O, S or NR b and R b is preferably hydrogen or C 1-3 is an alkyl group; Z is C 1-3 an alkylene group, more preferably a methylene group; Ring Q is R 7 a saturated 3- to 7-membered heterocyclic group substituted by a substituent; preferably, the saturated 3- to 7-membered heterocyclic group is selected from the group consisting of a piperidinyl group, a piperazinyl group, a pyrrolidinyl group, a morpholinyl group (e.g., a morpholino group), a thiomorpholinyl group (e.g., a thiomorpholino group), a tetrahydropyranyl group, and an azetidinyl group; R 7 is C 1-3 is an alkyl group; n is 0-2; The compound of claim 6.

8. A 0 is N; A 1 is N; A 2 is CH; A 3 is CH; R 0 is a cyano group; R 1 is a halogen, a hydroxy group, or C 1 -C 3 is an alkoxy group; R 2 is H; R 3 is hydrogen, halogen, C 1 -C 3 Alkyl group or halogenated C 1-3 is an alkyl group; R 4 is H; R 5 is hydrogen; R 6 is hydrogen; L is O; Z is C 1-3 an alkylene group, more preferably a methylene group; Ring Q is an unsubstituted saturated 3- to 7-membered heterocyclic group; preferably, the unsubstituted saturated 3- to 7-membered heterocyclic group is selected from the group consisting of a piperidinyl group, a piperazinyl group, a pyrrolidinyl group, a morpholinyl group (e.g., a morpholino group), a thiomorpholinyl group (e.g., a morpholino group), and an azetidinyl group; n is 0; The compound of claim 6.

9. The compound is selected from the group consisting of: (S)-5-((5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)picolinonitrile; (R)-5-((5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((4-methylmorpholin-2-yl)methoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)—N-(5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyrazin-2-amine; (S)—N-(5-(2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)-5-methylpyrazin-2-amine; (R)-5-((5-(2-methoxy-6-(morpholin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(piperazin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((1-methylpiperazin-2-yl)methoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-methoxy-6-(piperidin-4-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-fluoro-2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(3-chloro-2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(3-chloro-6-methoxy-2-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-methoxy-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(morpholin-2-ylmethoxy)-4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-(morpholin-2-ylmethoxy)-6-(trifluoromethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((morpholin-2-ylmethyl)amino)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(methyl(morpholin-2-ylmethyl)amino)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-methoxy-6-(2-(piperazin-1-yl)ethyl)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-6-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)nicotinonitrile; (S)-6-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyridazine-3-carbonitrile; (S)-5-methoxy-N-(5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)pyrazin-2-amine; (S)-5-ethyl-N-(5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)pyrazin-2-amine; (S)-5-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)-3-methylpyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)-6-methylpyrazine-2-carbonitrile; 5-((5-(2-methoxy-6-(piperidin-4-yloxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((1-methylpiperidin-3-yl)methoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (R)-5-((5-(2-methoxy-6-(piperidin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-((tetrahydro-2H-pyran-3-yl)methoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-ethoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-isopropoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(3-fluoro-2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-fluoro-2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-fluoro-2-methoxy-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-3-methyl-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-4-methyl-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-4-methyl-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)-4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-chloro-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-hydroxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-((4,4-dimethylpiperidin-3-yl)methoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-((4,4-dimethylpiperidin-3-yl)methoxy)-4-fluoro-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-4-methyl-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((4-bromo-5-(2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-6-fluorophenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2,4-difluoro-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-fluoro-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-fluoro-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-fluoro-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-fluoro-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-6-fluoro-4-methylphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-4-methyl-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-4-methyl-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-fluoro-4-methyl-6-(morpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (R)-5-((5-(2-methoxy-6-(pyrrolidin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (R)-5-((5-(4-fluoro-2-methoxy-6-(pyrrolidin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-4-chloro-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-methoxy-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-4-bromo-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-methoxy-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (R)-5-((5-(4-bromo-2-methoxy-6-(pyrrolidin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-((5-(2-(azetidin-3-ylmethoxy)-6-methoxy-4-methylphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-4-methyl-6-(pyrrolidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (R)-5-((5-(2-methoxy-4-methyl-6-(pyrrolidin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-ethyl-2-methoxy-6-(piperidin-3-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-fluoro-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(4-fluoro-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-chloro-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(4-chloro-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(4-bromo-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(4-bromo-2-methoxy-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; (S)-5-((5-(2-methoxy-4-methyl-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and (R)-5-((5-(2-methoxy-4-methyl-6-(thiomorpholin-2-ylmethoxy)phenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, solvate, hydrate or prodrug thereof; The compound of claim 1.

10. The application of the compounds according to any one of claims 1 to 9 in the manufacture of medicaments for the treatment or prevention of diseases, disorders and conditions associated with continuous activation of CHK1 or high internal DNA damage or lesions during DNA replication; preferably, said diseases, disorders and conditions are cancer.

11. The cancer is selected from the following group: liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilms' tumor, cervical cancer, testicular cancer, soft tissue sarcoma, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, small cell lung cancer, gastric cancer, colon cancer, malignant pancreatic islet tumor, malignant carcinomatous carcinoma, choriocarcinoma, fungal mycosis, head and neck cancer, osteogenic sarcoma, pancreatic cancer, acute myeloid leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary tumor, thyroid cancer, esophageal cancer, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial cancer, multiple erythrocyte carcinoma, idiopathic thrombocytemia, adrenocortical carcinoma, An application of claim 10.

12. The pharmaceutical product further comprises at least one known anti-cancer drug or a pharmaceutically acceptable salt thereof; preferably, the one or more anti-cancer drugs are one or more anti-cancer drugs selected from the following group: busulfan, melphalan, chloroambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin. methicillin, mitoxantrone, methylhydroxyellipticine, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, capecitabine, methotrexate, 5-fluoro-2'-deoxyuridine, fludarabine, nelarabine, cytarabine, pralatrexate, pemetrexed, hydroxycarbamide, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, mAb, pancreatic tuzumab, necitumumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab, tositumomab, brentuximab, daratumumab, elotuzumab, T-DM1, ofatumumab, dinutuximab, blinatumomab, ipilimumab, Avastin, Herceptin, MabThera, imatinib, gefitinib, erlotinib, osimertinib, af Atinib, ceritinib, alectinib, crizotinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, Torisel, everolimus, vorinostat, romidepsin, panobinostat, belinstat, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, carfilzomib, ixazomib, vismodegib, sonidegib, denosumab, Thalidomide, lenalidomide, venetoclax, aldesleukin (recombinant human interleukin-2), sipuecel-T (prostate cancer treatment vaccine), palbociclib, olaparib, niraparib, rucaparib, talazoparib, and senaparib, 12. The compound of claim 11.

13. The application of claim 10, wherein the pharmaceutical agent is used in combination with radiation therapy.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition further comprises at least one known anticancer drug or a pharmaceutically acceptable salt thereof; preferably, the at least one known anticancer drug is selected from the following group: busulfan, melphalan, chloroambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, and mitoxan. thoron, methylhydroxyellipticine, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, capecitabine, methotrexate, 5-fluoro-2'-deoxyuridine, fludarabine, nelarabine, cytarabine, pralatrexate, pemetrexed, hydroxycarbamide, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, mAb, panitumumab, ne Situmumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab, tositumomab, brentuximab, daratumumab, elotuzumab, T-DM1, ofatumumab, dinutuximab, blinatumomab, ipilimumab, Avastin, Herceptin, MabThera, imatinib, gefitinib, erlotinib, osimertinib, afatinib Nib, ceritinib, alectinib, crizotinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, Toricel, everolimus, vorinostat, romidepsin, panobinostat, belinstat, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, carfilzomib, ixazomib, vismodegib, sonidegib, denosumab, Thalidomide, lenalidomide, venetoclax, aldesleukin (recombinant human interleukin-2), sipuecel-T (prostate cancer treatment vaccine), palbociclib, olaparib, niraparib, rucaparib, talazoparib, and senaparib, 15. The pharmaceutical composition of claim 14.